

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07050 A1

(51) International Patent Classification⁷: A61K 31/445,
31/46, 45/06, A61P 11/14

Ana; 1 Howell Drive, West Orange, NJ 07052 (US). CUSS,
Francis, M.; 14 Byrom Drive, Basking Ridge, NJ 07920
(US).

(21) International Application Number: PCT/US00/01853

(22) International Filing Date: 26 January 2000 (26.01.2000)

(74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough
Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill
Road, Kenilworth, NJ 07033-0530 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/359,771 26 July 1999 (26.07.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM,
EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG,
KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK,
MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA.

(71) Applicant: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
(US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors: TULSHIAN, Deen; 4 Saddle Ridge Drive,
Lebanon, NJ 08833 (US). HO, Ginny, D.; 42 Chestnut Hill
Drive, Murray Hill, NJ 07974 (US). SILVERMAN, Lisa,
S.; 214 Hana Road, Edison, NJ 08817 (US). MATASI,
Julius, J.; 129 Spruce Mill Lane, Scotch Plains, NJ 07076
(US). McLEOD, Robbie, L.; 13 Creek Trail, Branchburg,
NJ 08876 (US). HEY, John, A.; 122 Hopper Avenue, Nut-
ley, NJ 07110 (US). CHAPMAN, Richard, W.; 30 Dit-
mars Circle, Somerville, NJ 08876 (US). BERCOVICI,

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH



(57) Abstract: The present invention relates to the use of ORL-1 receptor ag-
onists for the treatment of cough, alone or in combination with one or more
agents for the treatment of cough, allergy or asthma symptoms, in particular
to the use of ORL-1 agonists of formula (I) or a pharmaceutically acceptable
salt or solvate thereof, wherein: the dotted line represents an optional double
bond; X¹ is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or hetero-
cycloalkyl; X² is -CHO, -CN, optionally substituted amino, alkyl, or aryl; or X¹
is optionally substituted benzofused heterocyclyl and X² is hydrogen; or X¹ and
X² together form an optionally benzofused spiro heterocyclyl group R¹, R², R³
and R⁴ are independently H and alkyl, or (R¹ and R⁴) or (R² and R³) or (R¹
and R³) or (R² and R⁴) together can form an alkylene bridge of 1 to 3 carbon
atoms; Z¹ is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or hetero-
cycloalkyl, or -CO₂(alkyl or substituted amino) or CN; Z² is H or Z¹; Z³ is H or
alkyl; or Z¹, Z² and Z³, together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings.

WO 01/07050 A1

5

NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH

10 BACKGROUND

The nociceptin receptor ORL-1 has been shown to be involved with modulation of pain in animal models. ORL-1 (the nociceptin receptor) was discovered as an "orphan opioid-like receptor" i.e. a receptor whose ligand was unknown. The nociceptin receptor is a G protein coupled receptor. While highly related in structure to the three classical opioid receptors, i.e. the targets for traditional opioid analgesics, it is not activated by endogenous opioids. Similarly, endogenous opioids fail to activate the nociceptin receptor. Like the classical opioid receptors, the nociceptin receptor has a broad distribution in the central nervous system.

In late 1995, nociceptin, also known as Orphanin FQ (OFQ), was discovered and shown to be an endogenous peptide ligand that activates the nociceptin receptor. Data included in the initial publications suggested that nociceptin and its receptor are part of a newly discovered pathway involved in the perception of painful stimuli. Subsequent work from a number of laboratories has shown that nociceptin, when administered intraspinally to rodents, is an analgesic. The efficacy of nociceptin is similar to that of endogenous opioid peptides. Recent data has shown that nociceptin acts as an anxiolytic when administered directly into the brain of rodents. When tested in standard animals models of anxiety, the efficacy of nociceptin is similar to that seen with classical benzodiazapine anxiolytics. These data suggest that a small molecule agonist of the nociceptin receptor could have significant analgesic or anxiolytic activity.

35 Additional recent data (Rizzi, et al, Life Sci., 64, (1999), p. 157-163) has shown that the activation of nociceptin receptors in isolated

guinea pig bronchus inhibits tachykinergic, non-adrenergic, non-cholinergic contractions, indicating that nociceptin receptor agonists could be useful in the treatment of asthma. Also, it has been reported (Ciccocioppo et al, Psychopharmacology, 141 (1999), p. 220-224) nociceptin reduces the rewarding properties of ethanol in msP alcohol preferring rats, suggesting that intervention of nociceptin could be useful in the treatment of alcohol abuse. In EP 856,514, 8-substituted 1,3,8-triazaspiro[4,5]decan-4-one derivatives were disclosed as agonists and/or antagonists of orphanin FQ (i.e., nociceptin) useful in the treatment of various disorders, including depression; 2-oxoimidazole derivatives disclosed in WO98/54168 were described as having similar utility. Earlier, benzimidazolyl piperidines were disclosed in U.S. 3,318,900 as having analgesic activity.

Potent analgesic agents such as traditional opioids, e.g. morphine, carry with them significant side-effects. Clinically relevant side-effects include tolerance, physical dependence, respiratory depression, sedation and a decrease in gastrointestinal motility. For many patients, particularly those subjected to chronic opioid therapy, i.e. cancer patients, these side effects limit the dose of opioid that can be administered. Clinical data suggests that more than one-third of cancer patients have pain which is poorly controlled by present agents. Data obtained with nociceptin suggest the potential for advantages over opioids. When administered chronically to rodents, nociceptin, in contrast to morphine, showed no addiction liability. Additionally, chronic morphine treatment did not lead to a "cross-tolerance" to nociceptin, suggesting that these agents act via distinct pathways.


Unexpectedly, we have found that ORL-1 receptor agonists are useful in the treatment of cough.

SUMMARY OF THE INVENTION

The present invention relates to the use of an ORL-1 receptor agonist in the treatment of cough. The use of any compound having ORL-1 agonist activity is claimed, but the following non-limiting list of compounds exemplifies ORL-1 agonists:

a) a compound represented by the structural formula:

-3-



or a pharmaceutically acceptable salt or solvate thereof, wherein:

the dotted line represents an optional double bond;


X¹ is R⁵-(C₁-C₁₂)alkyl, R⁶-(C₃-C₁₂)cycloalkyl, R⁷-aryl, R⁸-

5 heteroaryl or R¹⁰-(C₃-C₇)heterocycloalkyl;

X² is -CHO, -CN, -NHC(=NR²⁶)NHR²⁶, -CH(=NOR²⁶), -NHOR²⁶, R⁷-aryl, R⁷-aryl(C₁-C₆)alkyl, R⁷-aryl(C₁-C₆)alkenyl, R⁷-aryl(C₁-C₆)-alkynyl, -(CH₂)_vOR¹³, -(CH₂)_vCOOR²⁷, -(CH₂)_vCONR¹⁴R¹⁵, -


10 (CH₂)_vNR²¹R²² or -(CH₂)_vNHC(O)R²¹, wherein v is zero, 1, 2 or 3 and

or X¹ is



and X² is hydrogen;

15 or X¹ and X² together form a spiro group of the formula



m is 1 or 2;

n is 1, 2 or 3, provided that when n is 1, one of R¹⁶ and R¹⁷ is -C(O)R²⁸;


p is 0 or 1;

Q is -CH₂-, -O-, -S-, -SO-, -SO₂- or -NR¹⁷-;

R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen and (C₁-C₆)alkyl, or (R¹ and R⁴) or (R² and R³) or (R¹ and R³) or (R² and R⁴) together can form an alkylene bridge of 1 to 3 carbon atoms;

R⁵ is 1 to 3 substituents independently selected from the group consisting of H, R⁷-aryl, R⁶-(C₃-C₁₂)cycloalkyl, R⁸-heteroaryl, R¹⁰-(C₃-C₇)heterocycloalkyl, -NR¹⁹R²⁰, -OR¹³ and -S(O)₀₋₂R¹³;

R⁶ is 1 to 3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, R⁷-aryl, -NR¹⁹R²⁰, -OR¹³ and -SR¹³;


R⁷ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, R²⁵-aryl, (C₃-C₁₂)cycloalkyl, -CN, -CF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -OCF₃, -NR¹⁹R²⁰, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -NHSO₂R¹⁹, -SO₂N(R²⁶)₂, -SO₂R¹⁹, -SOR¹⁹, -SR¹⁹, -NO₂, -CONR¹⁹R²⁰, -NR²⁰COR¹⁹, -COR¹⁹, -COCF₃, -OCOR¹⁹, -OCO₂R¹⁹, -COOR¹⁹, -(C₁-C₆)alkyl-NHCOOC(CH₃)₃, -(C₁-C₆)alkyl-NHCOCF₃, -(C₁-C₆)alkyl-NHSO₂-(C₁-C₆)alkyl, -(C₁-C₆)alkyl-NHCONH-(C₁-C₆)alkyl or -(CH₂)_f-N  -R¹⁹, wherein f is 0 to 6; or R⁷ substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

R⁸ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, R²⁵-aryl, (C₃-C₁₂)cycloalkyl, -CN, -CF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -OCF₃, -NR¹⁹R²⁰, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -NHSO₂R¹⁹, -SO₂N(R²⁶)₂, -NO₂, -CONR¹⁹R²⁰, -NR²⁰COR¹⁹, -COR¹⁹, -OCOR¹⁹, -OCO₂R¹⁹ and -COOR¹⁹;

R⁹ is hydrogen, (C₁-C₆)alkyl, halo, -OR¹⁹, -NR¹⁹R²⁰, -NHCN, -SR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

R¹⁰ is H, (C₁-C₆)alkyl, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

R¹¹ is independently selected from the group consisting of H, R⁵-(C₁-C₆)alkyl, R⁶-(C₃-C₁₂)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl,

-(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰ and -(CH₂)_q-N  _a,

wherein q and a are as defined above;

R^{12} is H, (C₁-C₆)alkyl, halo, -NO₂, -CF₃, -OCF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

R^{13} is H, (C₁-C₆)alkyl, R⁷-aryl, -(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰; -(C₁-C₆)alkyl-SR¹⁹; or aryl (C₁-C₆) alkyl;

5 R^{14} and R^{15} are independently selected from the group consisting

of H, R⁵-(C₁-C₆)alkyl, R⁷-aryl and $-(CH_2)_q-\overset{\text{O}}{\underset{\text{O}}{\parallel}}\text{C}-\text{N}\left(\text{C}_6\text{H}_9\right)_a$, wherein q and a are as defined above;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, R⁵-(C₁-C₆)alkyl, R⁷-aryl, (C₃-C₁₂)cycloalkyl, R⁸-heteroaryl, 10 R⁸-heteroaryl(C₁-C₆)alkyl, -C(O)R²⁸, -(C₁-C₆)alkyl(C₃-C₇)-heterocycloalkyl, -(C₁-C₆)alkyl-OR¹⁹ and -(C₁-C₆)alkyl-SR¹⁹;


R^{19} and R^{20} are independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, aryl and aryl(C₁-C₆)alkyl;

R^{21} and R^{22} are independently selected from the group consisting 15 of hydrogen, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, (C₃-C₁₂)cycloalkyl(C₁-C₆)alkyl, (C₃-C₇)heterocycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)-heterocycloalkyl, R⁷-aryl, R⁷-aryl(C₁-C₆)alkyl, R⁸-heteroaryl(C₁-C₁₂)alkyl, -(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -(C₁-C₆)alkyl-SR¹⁹, -(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl and -(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl; 20

R^{18} is hydrogen or (C₁-C₆)alkyl;

Z¹ is R⁵-(C₁-C₁₂)alkyl, R⁷-aryl, R⁸-heteroaryl, R⁶-(C₃-C₁₂)cycloalkyl, R¹⁰-(C₃-C₇)heterocycloalkyl, -CO₂(C₁-C₆)alkyl, CN or -C(O)NR¹⁹R²⁰; Z² is hydrogen or Z¹; Z³ is hydrogen or (C₁-C₆)alkyl; or

25 Z¹, Z² and Z³, together with the carbon to which they are attached, form the group



the sum of w and u is 1-3; c and d are independently 1 or 2; s is 1 to 5; and ring A is a fused R⁷-phenyl or R⁸-heteroaryl ring;

R²³ is 1 to 3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ and -
5 (C₁-C₆)alkyl-NR¹⁹R²⁰;

R²⁴ is 1 to 3 substituents independently selected from the group consisting of R²³, -CF₃, -OCF₃, NO₂ or halo, or R²⁴ substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

10 R²⁵ is 1-3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, (C₁-C₆)alkoxy and halo;

R²⁶ is independently selected from the group consisting of H, (C₁-C₆)alkyl and R²⁵-C₆H₄-CH₂-;


R²⁷ is H, (C₁-C₆)alkyl, R⁷-aryl(C₁-C₆)alkyl, or (C₃-C₁₂)cycloalkyl;
15 and

R²⁸ is (C₁-C₆)alkyl, -(C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl, R⁷-aryl, R⁷-aryl-(C₁-C₆)alkyl, R⁸-heteroaryl, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -(C₁-C₆)alkyl-OR¹⁹ or -(C₁-C₆)alkyl-SR¹⁹.


20 Preferred compounds of formula I are those wherein Z¹ and Z² are each R⁷-aryl, particularly R⁷-phenyl. Preferred R⁷ substituents are (C₁-C₆)alkyl and halo, with ortho-substitution being more preferred.

Compounds of formula I wherein R¹, R², R³ and R⁴ are each hydrogen are preferred, as well as compounds wherein R¹ and R³ are
25 each hydrogen and R² and R⁴ are an alkylene bridge of 2 or 3 carbons.

Preferred are compounds of formula I wherein X¹ is R⁷-aryl, for example R⁷-phenyl, and X² is OH (i.e., X² is -(CH₂)_vOR¹³, wherein v is 0




and R¹³ is H) or -NC(O)R²⁸, compounds wherein X¹ is
wherein R¹² is hydrogen and R¹¹ is (C₁-C₆)alkyl, -(C₁-C₆)alkyl(C₃-
30 C₁₂)cycloalkyl, -(C₁-C₆)alkyl-OR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R²⁰; and compounds wherein X¹ and X² together form the spirocyclic group



Also preferred are compounds of formula I wherein X¹ and X² form a spiro group, Z¹ is R⁷-aryl, preferably R⁷-phenyl, and Z² is C₄₋₁₂-alkyl:

5

b) a compound disclosed in EP 856,514 represented by the structural formula II:



wherein

10 R^{1a} and R^{2a} are, independently from each other, hydrogen, lower alkyl, lower alkoxy or halogen;

R^{3a} is phenyl, optionally substituted by lower alkyl, CF₃, lower alkoxy or halogen; and

15 R^{4a} is hydrogen, lower alkyl, lower alkenyl, -C(O)-lower alkyl, -C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)-lower alkyl, lower alkanetriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF₃, phenyl or benzyl;

R^{5a} and R^{6a} are, independently from each other, hydrogen, phenyl, lower alkyl or di-lower alkyl or may form together a phenyl ring, and

20 R^{5a} and one of R^{1a} or R^{2a} may form together a saturated or unsaturated 6 membered ring,


A^a is a 4-7 membered saturated ring which may contain a heteroatom such as O or S,

or a pharmaceutically acceptable acid addition salt thereof.

25 Preferred compounds of formula II include:

(-)-8-(5,8-dichloro-1,2,3,4-tetrahydro-naphthyl-2)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

- 8-(8-chloro-1,2,3,4-tetrahydro-naphthyl-2)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;
 1-phenyl-8-(1,2,3,4-tetrahydro-naphthyl-1)-1,3,8-triaza-spiro[4.5]decan-4-one;
 5 8-indan-2-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;
 (RS)-8-(acenaphthen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;
 (RS)-8-(acenaphthen-1-yl)-3-methyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;
 (RS)-8-(2,3-dihydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;
 10 (R)-8-(acenaphthen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;
 8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one; and
 (RS)-8-(5-methyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-1,3,8-triaza-spiro[4.5]decan-4-one.
 15 c) a compound disclosed in EP 921,125 represented by the structural formula III




III

wherein

- 20 R^{1b} is hydrogen, lower alkyl, halogen, lower alkoxy, CF_3 , lower alkyl-phenyl or (C_{5-7}) -cycloalkyl;
 R^{2b} is hydrogen, lower alkyl, phenyl or lower alkyl-phenyl;
 R^{3b} is hydrogen, lower alkyl, benzyl, lower alkyl-phenyl, lower alkyl-diphenyl, triazinyl, cyanomethyl, lower alkyl-piperidinyl, lower alkyl-naphthyl, (C_{5-7}) -cycloalkyl, lower alkyl- (C_{5-7}) -cycloalkyl, lower alkyl-pyridyl,
 25 lower alkyl-morpholinyl, lower alkyl dioxolanyl, lower alkyl, oxazolyl, or lower alkyl-2-oxo-oxazolidinyl and wherein the ring systems may be substituted by additional lower alkyl, lower alkoxy, CF_3 or phenyl, or
 $-(CH_2)_nC(O)O$ -lower alkyl, $-(CH_2)_nC(O)NH_2$, $-(CH_2)_nC(O)N$ (lower alkyl) $_2$,
 30 $-(CH_2)_nOH$ or $-(CH_2)_nC(O)NHCH_2C_6H_5$;
 R^{4b} is hydrogen, lower alkyl or nitrilo;

A^b is a ring system, consisting of

(a) (C₅₋₁₅)-cycloalkyl, which may be in addition to R^{4b} optionally substituted by lower alkyl, CF₃, phenyl, (C₅₋₇)-cycloalkyl, spiro-undecan-alkyl or by 2-norbornyl, or is one of the following groups



5

dodecahydro-acenaphthylen-1-yl (e), bicyclo[6.2.0]dec-9-yl (f) and bicyclononan-9-yl (g); and wherein

R^{5b} and R^{6b} are hydrogen, lower alkyl, or taken together and with the carbon atoms to which they are attached form a phenyl ring;

10

R^{7b} is hydrogen or lower alkyl;

the dotted line represents an optional double bond and

n is 1 to 4;

or a pharmaceutically acceptable acid addition salt thereof.

Preferred compounds of formula III include:

15

8-(decahydro-naphthalen-2-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

8-(decahydro-naphthalen-2-yl)-3-methyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

a mixture of (2RS,4aRS,8aSR)- and (2RS,4aRS,8aSR)- 8-(decahydro-naphthalen-2-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

20

(2RS,4aSR,8aRS)-8-(decahydro-naphthalen-2-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

cis-8-(4-methyl-cyclohexyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

8-cyclodecyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

25

8-cyclononyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

cis-8-(4-isopropyl-cyclohexyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

(R,S)-8-cyclodecyl-1-(3-methyl-phenyl)-2-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

30


8-cyclodecyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl)-acetonitrile;

8-(cis-octahydro-inden-2-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one;

and

8-(cis-bicyclo[6.2.0]dec-9-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one.

d) a compound disclosed in WO 99/36421 represented by the structural formula IV:



- 5 or a pharmaceutically acceptable salt thereof, wherein
 R^{1c} and R^{2c} are independently C_1 - C_4 alkyl; or
 R^{1c} and R^{2c} , taken together with the carbon to which they are
attached, form a mono-, bi-, tri- or spiro-cyclic group having 6 to 13
carbon atoms, wherein the cyclic group is optionally substituted by 1 to 5
10 substituents independently selected from C_1 - C_4 alkyl, C_2 - C_4 alkylene,
 C_1 - C_4 alkoxy, hydroxy, oxo, $=CH_2$ and $=CH$ - C_1 - C_4 alkyl;
 R^{3c} is C_1 - C_7 alkyl, C_2 - C_5 alkenyl, C_2 - C_5 alkynyl, phenyl- C_1 - C_5 alkyl,
phenyl optionally substituted by 1 to 3 substituents independently
selected from fluorine, C_1 - C_3 alkyl and C_1 - C_3 alkoxy, or a heteroaryl group
15 selected from furyl, theinyl, pyrrolyl and pyridyl, wherein said heteroaryl
group is optionally substituted by 1 to 3 substituents independently
selected from halo, C_1 - C_3 alkyl and C_1 - C_3 alkoxy, with the proviso that
when both R^{1c} and R^{2c} are C_1 - C_4 alkyl, then R^{3c} is other than C_1 - C_7 alkyl,
 C_2 - C_5 alkenyl and C_2 - C_5 alkynyl;
20 R^{4c} is selected from
1) hydrogen;
2) optionally substituted mono- or di-substituted C_1 - C_8 alkyl,
 C_3 - C_7 cycloalkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, C_1 - C_6 alkyl- Z^c , C_1 - C_6 alkyl- Z^c -
(C_1 - C_6)alkyl, C_3 - C_7 cycloalkyl- Z^c -(C_1 - C_6)alkyl, C_2 - C_6 alkenyl- Z^c -(C_1 - C_6)alkyl or
25 C_2 - C_6 alkynyl- Z^c -(C_1 - C_6)alkyl, wherein Z^c is selected from O, S, SO, SO_2 ,
CO, CO_2 , OCO, NR^c , $CONR^c$ and NR^cCO , wherein R^c is hydrogen or C_1 -
 C_6 alkyl, and the substituents to be attached to the alkyl, alkenyl, alkynyl
or cycloalkyl moiety are independently selected from halo, hydroxy,
carboxy, amino, mono- or di-(C_1 - C_4 alkyl)amino, hydrazino, azido, ureido,
30 amidino and guanidino; or

3) optionally mono- or di-substituted aryl, heterocyclic, aryl(C₁-C₅)alkyl, heterocyclic(C₁-C₅)alkyl, heterocyclic-heterocyclic(C₁-C₅)alkyl, aryl-heterocyclic(C₁-C₅)alkyl, heterocyclic-Z^c-(C₁-C₅)alkyl, aryl-Z^c-(C₁-C₅)alkyl, aryl(C₁-C₅)alkyl-Z^c-(C₁-C₅)alkyl, or heterocyclic(C₁-C₅)alkyl-Z^c-(C₁-C₅)alkyl, wherein Z^c is selected from O, S, SO, SO₂, CO, CO₂, OCO, NR^c, CONR^c and NR^cCO, wherein R^c is hydrogen or C₁-C₆ alkyl, and the substituents to be attached to the aryl or heterocyclic moiety are independently selected from halo, hydroxy, carboxy, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-CO-, amino(C₁-C₄)alkyl-CO-, phenyl, benzyl, amino, mono- or di-(C₁-C₄ alkyl)amino, hydrazino, azido, ureido, amidino and guanidino;

R^{5c} is independently selected from halo, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkylsulfonyl, CF₃, carboxy, hydroxy, amino, alkylamino, acylamino, arylcarbonyl, alkylcarbonyl and hydroxyalkyl; and

n is 0, 1, 2, 3 or 4.

Preferred compounds of formula IV include:

- 1-{1-[1-methyl-1-(2-thienyl)ethyl]-4-piperidinyl}1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[4-piperidinyl-1-(1-propylcyclononyl)]-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[1-(1-phenylcyclooctyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[1-(1-phenylcyclononyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-{1-[1-(4-fluorophenyl)cycloheptyl]-4-piperidinyl}-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[1-(1-methylcyclononyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[1-(1-ethylcyclononyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;
- 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;


1-[1-(1-phenylcyclohept-4-enyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;

1-(6-aminoethyl)-3-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one;

5 1-(2-aminoethyl)-3-[1-(1-phenylcyclohept-4-enyl)-4-piperidinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one; and

1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-3-(2-piperidinoethyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one.

10 e) a compound disclosed in WO 98/54 168 represented by the structural formula V



or a salt or ester thereof, wherein

Ar^{1d} is an optionally substituted aromatic carbon ring or heterocycle, wherein the optional substituents are independently selected from halo, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy and carboxyl;


is an optionally substituted mono- or di-cyclic C₃₋₁₄ aliphatic nitrogenous heterocycle;

20 Cy^d is an optionally substituted mono-, di- or tri-cyclic C₃₋₂₀ aliphatic carbon ring;

R^{1d} is hydrogen, lower alkenyl, lower alkynyl, lower cycloalkyl, amino, lower alkylamino, di(lower alkyl)amino, hydroxy, lower alkoxy, carboxy, lower alkoxy carbonyl, carbamoyl, lower alkylcarbamoyl, di(lower alkyl)carbamoyl or optionally substituted lower alkyl; and

25 R^{2d} is hydrogen or lower alkyl.

f) a compound disclosed in WO 99/48492 represented by the structural formula VI



or a pharmaceutically acceptable salt thereof, wherein

30 A^e is an aryl or heterocyclyl ring;

B^e is phenyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, oxazolyl or cyclohexenyl;

R^{1e} and R^{2e} are independently hydrogen, alkyl, hydroxyalkyl, amino, alkylamino or di-alkylamino;

5 R^{3e} and R^{4e} are independently hydrogen, halo or alkyl;

X^e is hydrogen, halo, alkyl, alkoxyalkyl, alkenyl, amino, CN, or $-(CH_2)_{m^e}-E^e-(CH_2)_{n^e}-G^e$;

E^e is a bond, $-CH=CR^{6e}$, O, S, NR^{7e}, CO, SO₂ or NHCO;

10 G^e is aryl, heterocyclyl, cycloalkyl or fused aryl, all optionally substituted by 1-5 R^{5e} groups;

R^{5e} is independently selected from halo, OH, alkyl, alkyl optionally substituted by alkoxy, alkoxyalkoxy, halo, OH or alkanoyloxy, alkoxy, alkoxyalkoxy, amino, alkylamino, di-alkylamino, NO₂, CN, alkanoyl, alkanoyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl and phenyl;

15 R^{6e} is hydrogen or aryl;

R^{7e} is hydrogen, alkyl or alkoxycarbonyl;

m^e is 0-8; and

n^e is 1-4.

A preferred compound of formula VI is:

20 N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]benzamide.

The disclosures of EP 856,514, EP921,125, WO 99/36421, WO 98/54168 and WO 99/48492 are incorporated herein by reference. The compounds of formula I are described in greater detail below.

25 The invention also relates to the use of an ORL-1 agonist for the manufacture of a medicament for use in treating cough. In particular, the invention relates to the use in the manufacture of a medicament for treating cough comprising the use of a compound of any of formulas I to VI.

30 The invention also relates to a method of treating cough comprising administering to a mammal in need of such treatment an effective amount of an ORL-1 agonist. In particular, the invention relates to a method of treating cough comprising administering to a mammal in need of such treatment an effective amount of a compound of any of
35 formulas I to VI.

In another aspect, the invention relates to a method of treating cough comprising administering to a mammal in need of such treatment: (a) an effective amount of a nociceptin receptor ORL-1 agonist; and (b) an effective amount of one or more agents for treating cough, allergy or asthma symptoms selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H_3 inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK_1 , NK_2 and NK_3 tachykinin receptor antagonists, and GABA_B agonists.

In still another aspect, the invention relates to a pharmaceutical composition comprising a nociceptin receptor ORL-1 agonist and one or more agents selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H_3 inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK_1 , NK_2 and NK_3 tachykinin receptor antagonists, and GABA_B agonists.

Preferred ORL-1 agonists for use in the combination and in the combined pharmaceutical composition are those represented in formulas I to VI.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the effect in guinea pigs of Compounds A and B (see Example 12) compared to baclofen on capsaicin-induced cough.

Figures 2A and 2B show changes in Tidal Volume after administration of Compound A or baclofen, and Figure 2C shows changes in frequency of breaths after administration of Compound A or baclofen.

DETAILED DESCRIPTION OF THE INVENTION

As used herein in formula I, the following terms are as defined below unless otherwise indicated:

M^+ represents the molecular ion of the molecule in the mass spectrum and MH^+ represents the molecular ion plus hydrogen of the molecule in the mass spectrum;

Bu is butyl; Et is ethyl; Me is methyl; and Ph is phenyl;

alkyl (including the alkyl portions of alkoxy, alkylamino and dialkylamino) represents straight and branched carbon chains containing from 1 to 12 carbon atoms or 1 to 6 carbon atoms; for example methyl, ethyl, propyl, iso-propyl, n-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like;

alkenyl represents an alkyl chain of 2 to 6 carbon atoms comprising one or two double bonds in the chain, e.g., vinyl, propenyl or butenyl;

alkynyl represents an alkyl chain of 2 to 6 carbon atoms comprising one triple bond in the chain, e.g., ethynyl or propynyl;

alkoxy represents an alkyl moiety covalently bonded to an adjacent structural element through an oxygen atom, for example, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like;

aryl (including the aryl portion of arylalkyl) represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is phenyl), wherein said aryl group optionally can be fused with aryl, (C₃-C₇)cycloalkyl, heteroaryl or hetero(C₃-C₇)cycloalkyl rings; and wherein R⁷-aryl means that any of the available substitutable carbon and nitrogen atoms in said aryl group and/or said fused ring(s) is optionally and independently substituted, and wherein the aryl ring is substituted with 1-3 R⁷ groups. Examples of aryl groups are phenyl, naphthyl and anthryl;

arylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been substituted with one to three aryl groups; wherein aryl is as defined above;

aryloxy represents an aryl group, as defined above, wherein said aryl group is covalently bonded to an adjacent structural element through an oxygen atom, for example, phenoxy;

cycloalkyl represents saturated carbocyclic rings of from 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms; wherein R⁶-cycloalkyl means that any of the available substitutable carbon atoms in said cycloalkyl group is optionally and independently substituted, and wherein the cycloalkyl ring is substituted with 1-3 R⁶ groups;


cycloalkylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been

substituted with one to three cycloalkyl groups, wherein cycloalkyl is as defined above;

halo represents fluoro, chloro, bromo and iodo;


heteroaryl represents cyclic groups having one to three

- 5 heteroatoms selected from O, S and N, said heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic groups containing from 5 to 14 carbon atoms, wherein said heteroaryl group optionally can be fused with one or more aryl, cycloalkyl, heteroaryl or heterocycloalkyl rings; and wherein any of the available substitutable carbon or nitrogen atoms in said heteroaryl group and/or said fused ring(s) may be optionally and independently substituted, and wherein the heteroaryl ring can be substituted with 1-3 R^8 groups; representative heteroaryl groups can include, for example, furanyl, thienyl, imidazolyl, pyrimidinyl, triazolyl, 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl N-oxide
15 wherein pyridyl N-oxide can be represented as:




- heteroarylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heteroaryl groups, as defined above;
20

- heterocycloalkyl represents a saturated ring containing from 3 to 7 carbon atoms, preferably from 4 to 6 carbon atoms, interrupted by 1 to 3 heteroatoms selected from -O-, -S- and -NR²¹-, wherein R²¹ is as defined above, and wherein optionally, said ring may contain one or two unsaturated bonds which do not impart aromatic character to the ring; and wherein any of the available substitutable carbon atoms in the ring may substituted, and wherein the heterocycloalkyl ring can be substituted with 1-3 R^{10} groups; representative heterocycloalkyl groups include 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 1-, 2-, 3- or 4-piperidinyl, 2- or 3-pyrrolidinyl, 1-, 2- or 3-piperazinyl, 2- or 4-dioxanyl, morpholinyl,
25 30



When the optional double bond in the piperidiny ring of formula I is present, one of X¹ and X² forms the bond with the 3-position carbon and the remaining X¹ or X² is not hydrogen.

- When X¹ and X² in formula I form a spiro group as defined
 5 above, the wavy lines in the structures shown in the definition indicate the points of attachment to to the 4-position carbon of the piperidiny ring, e.g., compounds of the following formulas are formed:



- Certain compounds of formula I may exist in different
 10 stereoisomeric forms (e.g., enantiomers, diastereoisomers and atropisomers). The invention contemplates all such stereoisomers both in pure form and in mixture, including racemic mixtures.

- Certain compounds used in the invention will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl
 15 group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

- Certain basic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric,
 25 acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be
 30 regenerated by treating the salt with a suitable dilute aqueous base


solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention.

All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Compounds of formula I can be prepared by known methods from starting materials either known in the art or prepared by methods known in the art. Examples of general procedures and specific preparative examples are given below.

Typically, X¹,X²-substituted piperidines are alkylated with Z¹,Z²,Z³-substituted halomethanes in the presence of excess bases such as K₂CO₃ and Et₃N, in solvents such as DMF, THF or CH₃CN, at room temperature or at elevated temperatures.

X¹,X²-substituted piperidines are either commercially available or made by known procedures. For example, 4-hydroxy-4-phenyl-piperidine can be converted to a 4-*t*Boc-amino-4-phenylpiperidine according to the following reaction scheme, wherein Bn is benzyl, Ph is phenyl and *t*Boc is *t*-butoxycarbonyl:




Commercially available 4-phenyl-4-piperidinol is protected with a benzyl group and the resulting intermediate is then treated with Me₃SiCN. The resultant amide is hydrolyzed with aqueous HCl in CH₃OH to produce the 4-amino compound. The amino group is protected with *t*Boc and the N-

benzyl group is removed by hydrogenolysis to produce the desired 4-amino-piperidine derivative.

The 4-(protected)amino-piperidine then can be reacted with a Z^1, Z^2, Z^3 -halomethane and the protecting group removed. The amine (i.e., X^2 is $-NH_2$) can undergo various standard conversions to obtain amine derivatives. For example, the amine of formula I can be reacted with a R^{22} -carboxaldehyde in the presence of a mild reducing agent such as $Na(OAc)_3BH$ or with a compound of the formula $R^{22}-L$, wherein L is a leaving group such as Cl or Br, in the presence of a base such as Et_3N .


An alternative method for preparing compounds of formula I wherein X^1 is R^7 -aryl and X^2 is OH involves alkylating a 4-piperidone hydrochloride with a Z^1, Z^2, Z^3 -halomethane, then reacting the ketone with an appropriately substituted R^7 -phenylmagnesium bromide or with a compound of the formula X^1-L^1 , wherein L^1 is Br or I, and n-butyl-lithium.

X^1, X^2 -substituted compounds of formula I can be converted into other compounds of formula I by performing reactions well known in the art on the X^1 and/or X^2 substituents. For example, a carboxaldehyde-substituted piperidine (i.e., X^2 is $-CHO$) can be converted to a substituted piperidine wherein X^2 is $R^{13}-O-CH_2-$, as shown in the following procedure for a compound of formula I wherein X^1 is phenyl, Z^1 and Z^2 are each phenyl, and R^1, R^2, R^3 and R^4 , and Z^3 are H :



A cyano-substituted piperidine (i.e., X^2 is $-CN$) can be converted to a substituted piperidine wherein X^2 is $R^{21}R^{22}N-CH_2-$ or X^2 is


$R^{28}C(O)NH-CH_2-$, as shown in the following procedure for a compound of formula I wherein X^1 is phenyl, R^{21}, R^1, R^2, R^3 and R^4 , and Z^3 are H, and L is a leaving group such as Cl or Br:



Compounds of formula I wherein X^1 is a benzofused nitrogen-containing heterocycle having an R^{11} substituent other than hydrogen are prepared by reacting the corresponding compounds wherein R^{11} is hydrogen with a compound of the formula R^{11}L (R^{11} is not H, and L is as defined above).


Alternatively, X^1, X^2 -substituted piperidine starting materials can be converted into other X^1, X^2 -substituted piperidines by similar procedures before reacting with the Z^1, Z^2, Z^3 -substituted halomethane.

For compounds of formula I wherein $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 variously form alkylene bridges, commercially available N-protected 4-piperidones are treated with phenyl lithium and resulting intermediate is deprotected to produce the desired compounds, for example:



wherein Pr is a N-protecting group, Ph is phenyl and z is 1-2.

The Z^1, Z^2, Z^3 -halomethyl derivatives wherein Z^1 and Z^2 are R^7 -phenyl are either commercially available or can be prepared using the procedure shown in the following reaction scheme:




Similar procedures, or others known in the art, can be used to prepare compounds wherein the Z substituents are other than phenyl.


- Compounds of formula I and preparative starting materials thereof, are exemplified by the following examples, which should not be construed as limiting the scope of the disclosure.

The following solvents and reagents are referred to herein by the abbreviations indicated: tetrahydrofuran (THF); ethanol (EtOH); methanol (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc); N,N-dimethylformamide (DMF); and diethyl ether (Et₂O). Room temperature is abbreviated as rt.

Example 1




- A mixture of 4-hydroxy-4-phenyl piperidine (1.5 g, 8.47 mmol) and K₂CO₃ (3.0 g, 21.73 mmol) in CH₃CN was stirred at rt. To this was added α-bromo-diphenylmethane (2.5 g, 10.12 mmol) and the reaction was stirred overnight. The reaction mixture was concentrated, redissolved in CH₂Cl₂, washed with water, dried (MgSO₄) and concentrated. Chromatography (SiO₂, 9:1 hexane/EtOAc) gave the title compound (2.6g, 90%). ¹H NMR (CDCl₃): δ 1.80 (m, 2H), 2.25 (m, 2H), 2.42 (m, 2H), 2.90 (m, 2H), 4.40 (s, 1H), 7.2-7.6 (m, 15H).

Example 2

Step 1: A solution of 4-piperidone monohydrate hydrochloride (5 g, 32.6 mmol) in CH₃CN was alkylated using the procedure described in Example


- 5 1. Chromatography of the residue on silica (95:5 hexane/ EtOAc) gave the desired compound.

Step 2: 4-Methylphenylmagnesium bromide (0.5 M in THF, 1.75 ml, 0.87 mmol) was added to a solution of product of Step 1 (191 mg, 0.72 mmol) in THF dropwise at 0°C. The solution was stirred at 0 for 2h, quenched
10 with ice-H₂O, extracted with EtOAc, washed with H₂O and brine, dried, and concentrated. Chromatography of the residue on silica (95:5 hexane/EtOAc, 93:7 hexane/EtOAc) gave the title compound (0.091 g, 30%). ¹H NMR (CDCl₃) δ 7.5 (m, 6H, ArH), 7.3 (t, 4H, ArH), 7.2 (t, 4H, ArH), 4.35 (s, 1H), 2.8 (d, 2H), 2.4 (m, 5H), 2.2 (td, 2H), 1.75 (d, 2H);
15 MS (CI) 358 (M+1); Elemental analysis for C₂₅H₂₇NO·1.2 H₂O: calcd: C 79.2, H 7.82, N 3.69; observed: C 78.90, H 8.02, N 3.85.

Example 3

- Add n-BuLi (2.5 M, 0.38 ml, 0.95 mmol) to a solution of 3-bromo-
20 thiophene (0.15g, 0.95 mmol) in Et₂O dropwise at -70°C and stir for 2h. Add a solution of the product of Step 1 of Example 2 (230 mg, 0.87 mmol) in Et₂O (4 ml) to the reaction mixture, slowly warm to rt over a period of 3 h, quench with ice-cooled NH₄Cl (aq), extract with Et₂O, wash with H₂O and brine, dry, and concentrate. Chromatograph the residue (95:5
25 hexane/EtOAc) to give the title compound (90 mg).


¹H NMR (CDCl₃) δ 7.5 (d, 2H), 7.35 (bt, 4H), 7.25 (m, 3H), 7.2 (m, 2H), 4.4 (s, 1H), 2.8 (d, 2H), 2.5 (t, 2H), 2.3 (dt, 2H), 2.0 (d, 2H); MS (CI) 350 (M+1); Elemental analysis for C₂₂H₂₂NOS.1.1 HCl.0.9 H₂O: calcd: C 65.11, H 6.43, N 3.54, S 7.8, Cl 9.61; observed: C 65.27, H 6.54, N 3.45, S 7.30, Cl 9.43.

Example 4

Step 1: 4-Phenyl-4-piperidinecarboxaldehyde (1.0 g, 5.29 mM) was alkylated using the procedure of Example 1, Step 1, to obtain the desired product (1.69g, 90%). ¹H NMR (CDCl₃): δ 2.40 (m, 4H), 2.50 (m, 2H), 2.85 (m, 2H), 4.25 (s, 1H), 7.20-7.50 (m, 15H), 9.42 (s, 1H).


Step 2: A solution of the product from Step 1 (3.0 g, 8.45 mmol) was cooled to 0°C and treated with NaBH₄ (1.0 g, 26.32 mmol). After 0.5 h, reaction mixture was treated with 1N HCl and concentrated. The residue was extracted with CH₂Cl₂, dried (MgSO₄) and evaporated. Column chromatography on the residue (4:1 hexane:EtOAc) produced desired primary alcohol. ¹H NMR (CDCl₃): δ 2.00 (m, 2H), 2.25 (m, 4H), 2.65 (m, 2H), 3.65 (d, 2H), 4.20 (s, 1H), 4.25 (d, 1H), 7.2-7.6 (m, 15H).

Step 3: The product of Step 2 was treated with NaH in DMF at 0°C for 0.5h. CH₃I was added and reaction was warmed up to rt. After stirring overnight, the reaction mixture was poured on ice, extracted with Et₂O, dried (MgSO₄) and evaporated. Column chromatography on the residue produced the title compound. ¹H NMR (CDCl₃): δ 2.10 (m, 4H), 2.40 (m, 2H), 2.78 (m, 2H), 2.90 (m, 2H), 3.00(s, 3H), 4.38 (s, 1H), 7.21-7.52 (m, 15H).


Example 5

- Step 1: A solution of 4-cyano-4-phenylpiperidine hydrochloride (5.0 g, 22.4 mM) in DMF (30 ml) was treated with Et₃N (7.20 ml, 47 mM) and bromodiphenylmethane (6.38 g, 25.80 mM) and stirred at rt under N₂ for 20h. The reaction mixture was concentrated in vacuo and partitioned between EtOAc and H₂O. The organic layer was washed with twice with water, then brine, and dried (MgSO₄), filtered and concentrated. Chromatography (SiO₂, 19:1 hexane/EtOAc) gave 6.0 g (76%) of the desired product. ¹H NMR (CDCl₃): δ 2.21 (m, 4H), 2.49 (t, J=12.3Hz, 2H), 3.11 (d, J=12.5 Hz, 2H), 4.46 (s, 1H), 7.45 (m, 15H).
- 5 Step 2: A solution of the product (6.0 g, 17 mM) of Step 1 in Et₂O (40 ml) was cooled to 0°C and treated with a 1M solution of LAH (34.10 ml, 34 mM), dropwise, under N₂, over 0.5 h. The reaction mixture was allowed to warm to rt and then refluxed for 4h. The reaction mixture was cooled to 0°C and treated with water (8 eq.). The reaction mixture was allowed to warm to rt and was stirred for 1 h. The resultant solid was filtered off and rinsed with Et₂O, and the filtrate was concentrated to yield 5.45 g (90%) of desired product. ¹H NMR (CD₃OD): δ 1.84 (m, 2H), 2.16 (m, 4H), 2.56 (m, 2H), 2.68 (m, 2H), 4.07 (s, 1H), 7.25 (m, 15H).
- 10 Step 3: A solution of the product (0.2 g, 0.56 mM) of Step 2 in CH₂Cl₂ (3 ml) was treated with benzoyl chloride (0.078 ml, 0.673 mM) and pyridine (0.045g, 0.568 mM) at rt for 18 h under N₂. The reaction mixture was concentrated, then partitioned between H₂O and CH₂Cl₂. The organic layer was washed with water (2x) and brine, then dried (MgSO₄), filtered and concentrated. Chromatography (SiO₂, 3:1 hexane/EtOAc) gave 0.2 g (77%) of the desired product. ¹H NMR (CD₃OD): δ 2.13 (m, 6H), 2.66 (m, 4H), 3.50 (s, 2H), 4.07 (s, 1H), 7.11-7.65 (m, 20H).
- 20 Step 4: A solution of the product (0.075 g, 0.16 mM) of Step 3 in THF (3 ml) was cooled to 0°C with stirring. LAH (solid, 0.025 g, 0.65 mM) was added under N₂ and stirring was continued for 0.25h. The reaction mixture was then refluxed for 5 h, then stirred at rt for 18h. The reaction mixture was cooled to 0°C and quenched with water (8 eq). The reaction mixture was allowed to warm to rt and was stirred for 1 h. The resultant solid was filtered off and rinsed with Et₂O, the filtrate was dried (MgSO₄) and concentrated. Chromatography (neutral Al₂O₃, CH₂Cl₂, then 3:1 CH₂Cl₂:EtOAc) gave 0.014 g (20%) of the title compound.
- 25
30
35

^1H NMR (CD_3OD): δ 1.90 (m, 2H), 2.15 (m, 4H), 2.48 (m, 2H), 2.68 (s, 2H), 3.53 (s, 2H), 4.05 (s, 1H), 7.01-7.38 (m, 20H).

Example 6


- 5 The product of Example 5, Step 2 (0.2 g, 0.561 mM), acetic anhydride (3 ml) and Et_3N (0.096 ml, 0.67 mM) were combined and stirred at rt for 18h. The reaction mixture was concentrated and partitioned between H_2O and CH_2Cl_2 . The organic layer was washed with water (2x), brine, then dried (MgSO_4), filtered and concentrated to
- 10 give 0.214 g (95%) of the title compound. ^1H NMR (CD_3OD): δ 1.87 (m, 5H), 2.16 (m, 4H), 2.61 (m, 2H), 3.31 (s, 2H), 4.07 (s, 1H), 7.12-7.40 (m, 20H).

Example 7

- 15 Step 1: A solution of 4-phenyl-4-hydroxy piperidine (10.0 g, 56.4 mM) in DMF (60 ml) was treated with Et_3N (8.28 ml, 59.2 mM) and benzyl bromide (7.37 ml, 62.10 mM) and stirred at rt under N_2 for 20 h. The reaction mixture was concentrated in vacuo, basified to pH 8 with saturated NaHCO_3 and partitioned between EtOAc and H_2O . The
- 20 organic layer was washed twice with water, then brine, and dried (MgSO_4), filtered and concentrated. Chromatography (neutral Al_2O_3 , hexane, then 1:1 hexane:EtOAc) gave 11.95 g (80%) of the desired product.
- Step 2: To a mixture of the product (30.0 g, 0.112 mol) of Step 1 and
- 25 (CH_3) $_3\text{SiCN}$ (59.94 ml, 0.448 mol), cooled to -15°C in an ethylene glycol/ CO_2 bath, under N_2 , is added glacial AcOH (47 ml) dropwise, while maintaining an internal temperature of -15°C . Concentrated H_2SO_4 (47 ml, 0.34 M) is added dropwise, with vigorous stirring, while maintaining an

- internal temperature of -15°C . The cooling bath was then removed and reaction mixture was stirred at rt for 18h. The reaction mixture was poured on ice and adjusted to pH 7 with a 50% NaOH solution while maintaining a temperature of 25°C . The reaction mixture was then
- 5 extracted with CH_2Cl_2 , and the organic layer was washed with water (2x), then brine, and dried (MgSO_4), filtered and concentrated.
- Recrystallization with EtOAc/hexane (1:10) gave 22.35 g (68%) of desired compound. ^1H NMR (CD_3OD): δ 2.10 (m, 2H), 2.40 (m, 4H), 2.82 (d, $J=11.50$ Hz, 2H), 3.57 (s, 2H), 7.20-7.43 (m, 10H), 8.05 (s, 1H).
- 10 Step 3: The product of Step 2 (20 g, 67.9 mM) and 5% (w/w) concentrated HCl (aq)/ CH_3OH (350 ml) were stirred under N_2 for 48 h. The mixture was concentrated to yield a foam which was suspended in Et_2O and concentrated to remove excess HCl. The resultant solid was resuspended in Et_2O , collected by vacuum filtration, washed with Et_2O
- 15 and dried under vacuum to give (23 g, 100%) of desired product. ^1H NMR (CD_3OD) of di-HCl salt: δ 2.59 (t, $J=13.3$ Hz, 2H), 2.93 (t, $J=13.3$ Hz, 2H), 3.07 (d, $J=13.50$ Hz, 2H), 3.58 (d, $J=13$ Hz, 2H), 4.26 (s, 2H), 7.56 (m, 10H).
- Step 4: The product of Step 3 (24.10 g, 71 mM), CH_2Cl_2 (300 ml),
- 20 (tBoc) $_2\text{O}$ (17.0 g, 78.1 mM) and Et_3N (14.37 g, 0.142 M) were combined and stirred under N_2 , at rt, for 18hrs. The reaction mixture was partitioned between CH_2Cl_2 and H_2O , and the aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were washed with water (2x), then brine, and dried (MgSO_4), filtered and concentrated. The
- 25 resulting solid was suspended in Et_2O and sonicated, filtered and dried to produce the desired compound (21.98 g, 90%). ^1H NMR (CD_3OD): δ 1.09 (bs, 2H), 1.39 (s, 1H), 2.05 (m, 2H), 2.34 (m, 4H), 2.65 (d, $J=11.8$ Hz, 2H), 3.56 (s, 2H), 7.18-7.40 (m, 10H).
- Step 5: The product of Step 4 (5.22 g, 14.2 mM), CH_3OH (430 ml).
- 30 Pd(OH) $_2/\text{C}$ (3.0 g) and NH_4COOH (18.86 g, 0.298 M) were combined and refluxed under N_2 for 8h. The reaction mixture was filtered using celite, washing with CH_3OH . The combined filtrates were concentrated to produce (3.90 g, 97%) of the desired product. ^1H NMR (CD_3OD): δ 1.10 (bs, 2H), 1.39 (s, 7H), 1.90 (m, 2H), 2.26 (m, 4H), 2.92 (m, 4H), 7.17-7.41
- 35 (m, 5H).


- Step 6: The product of Step 5 (2.74 g, 9.91 mM), CH₃CN (85 ml), Et₃N (1.75 ml, 12.40 mM) and bromodiphenylmethane (2.70 g, 10.9 mM) were combined and stirred at rt under N₂ for 18hrs. The mixture was concentrated and the resultant residue was partitioned between H₂O and EtOAc. The EtOAc layer was washed with water (2x), brine, then dried (MgSO₄), filtered and concentrated. Chromatography (neutral Al₂O₃, hexane, then 4:1 hexane:EtOAc) gave 2.85 g (65%) of the desired product. ¹H NMR (CD₃OD): δ 1.07 (bs, 2H), 1.37 (s, 7H), 2.23 (m, 2H), 2.24 (m, 4H), 2.74 (d, J= 12.1 Hz, 2H), 4.27 (s, 1H), 7.10-7.47 (m, 15H).
- Step 7: The product of Step 6 (4.6 g, 10 mM), 1,4-dioxane (38 ml) and 4 M HCl in 1,4-dioxane (25 ml, 101 mM) were combined and stirred at rt under N₂ for 4 h. The mixture was concentrated and the residue was suspended in Et₂O and re-concentrated. The resultant solid was resuspended in Et₂O, sonicated and the product was collected by vacuum filtration and dried to give 3.27 g (80% of the desired product). ¹H NMR (CD₃OD) of di-HCl salt: δ 2.91(m, 8H), 5.34 (s, 1H), 7.37-7.77 (m, 15H).
- Step 8: To a suspension of the product of Step 7 (0.3 g, 0.722 mM) in CH₂Cl₂ (3 ml), under N₂ at rt, was added 2-thiophenecarboxaldehyde (0.133 ml, 1.44 mM). The pH of the reaction was adjusted to 6 with Et₃N and the mixture was stirred for 0.5 h. Na(OAc)₃BH (0.230 g, 1.08 mM) was then added and the reaction mixture was stirred at rt under N₂ for 3 h. The reaction was quenched with saturated NaHCO₃(aq) and partitioned between Et₂O and H₂O. The organic layer was washed with H₂O (2x), brine, dried (MgSO₄), filtered and concentrated. Chromatography (SiO₂, toluene, then 1:19 EtOAc: toluene) gave 0.158 g (50%) of the desired product. ¹H NMR (CD₃OD): δ 1.96 (m, 2H), 2.17 (m, 2H), 2.52 (m, 4H), 3.45 (s, 2H), 4.24 (s, 1H), 6.76 (d, J=3.5 Hz, 1H), 6.85 (dd, J=3.6 Hz, 1H), 7.13-7.50 (m, 16H).

Example 8


Step 1: Alkylate a solution of 4-(2-oxo-1-benzimidazolyl)-piperidine in CH₃CN using the procedure described in Step 1 of Example 1 to produce the desired compound.

Step 2: Add NaH to a solution of 3-[1-(diphenylmethyl)-4-piperidiny]-1,3-dihydro-2H-benzimidazo-1-one (2.5 g, 6.6 mmol) in DMF (25 ml) and stir at rt for 1 h. Add n-butyl iodide to the mixture at rt and stir overnight. Quench with ice-H₂O, extract with EtOAc, wash with H₂O and brine, dry (MgSO₄) and concentrate. Chromatograph the residue on silica (1:9 EtOAc/hexane) to give the title compound (2.35 g). Dissolve the title compound in Et₂O, add HCl in Et₂O (8 ml, 1 M), stir for 1 h and filter to give the HCl salt. ¹H NMR (CDCl₃) δ 7.55 (m, 4H, ArH), 7.35 (m, 5H, ArH), 7.25 (m, 2H, ArH), 7.15 (m, 2H, ArH), 7.1 (m, 1H, ArH), 4.4 (m, 2H), 3.95 (t, 2H), 3.15 (d, 2H), 2.6 (dq, 2H), 2.1 (t, 2H, 1.8, m, 4H), 1.5 (m, 2H), 1.0 (t, 3H); ESI-MS 440 (M+1); Elemental analysis for C₂₉H₃₃N₃O.HCl.H₂O: calcd: C 70.5, H 7.3, N 8.5, Cl 7.18; observed: C 70.48, H 7.28, N 8.49, Cl 7.49).

Example 9




Add SOCl₂ (247 mg, 2.07 mmol) to a solution of 2-(chlorophenyl)phenylmethanol (300 mg, 1.38 mmol) in CH₂Cl₂ at rt, stir at rt for 5 h and concentrate. Dissolve the residue in CH₃CN, add K₂CO₃, 4-hydroxy-4-phenylpiperidine and NaI. Stir the solution at reflux overnight, filter and concentrate. Chromatograph the residue on silica (9:1 hexane/EtOAc) to give the title compound. ¹H NMR (CDCl₃) δ 7.91 (d, 1H), 7.58 (d, 2H), 7.54 (d, 2H), 7.42 (t, 2H), 7.32 (m, 5H), 7.26 (t, 3H), 7.16 (t, 3H), 5.0 (s, 1H), 2.8 (dd, 2H), 2.5 (dq, 2H), 2.2 (dt, 2H), 1.75 (d, 2H). Dissolve the title compound in ether, add HCl/Et₂O (1 M) to give the HCl salt. MS Cl (378 (M+1); Elemental analysis for C₂₄H₂₄NOCl.HCl.0.2H₂O: calcd: C 68.97, H 6.13, N 3.35, Cl 16.96; observed: C 68.87, H 6.04, N 3.35, Cl 17.00.

Example 10

Step 1: Alkylate a solution of 4-piperidone monohydrate hydrochloride (880 mg, 5 mmol) in CH₃CN with mandelonitrile (1 g, 7.51 mmol) using the procedure described in Example 9. Chromatography of the residue on silica followed by recrystallization (EtOAc) gives the desired compound (630 mg).

Step 2: Add a solution of 2-methoxyphenylmagnesium bromide in THF (24 ml, 0.5 M, 11.85 mmol) to a solution of the product of Step 1 (330 mg, 1.185 mmol) in THF at 0°C. Remove the ice-bath and stir the reaction mixture at reflux for 6 h. Quench the reaction with NH₄Cl (aq), extract with EtOAc, wash with brine, dry and concentrate. Chromatograph the residue (95:5, 9:1 hexane/EtOAc) to give the title compound (330 mg). ¹H NMR (CDCl₃) δ 7.76 (d, 1H), 7.62 (d, 1H), 7.55 (d, 1H), 7.45 (t, 1H), 7.34 (m, 3H), 7.24 (m, 2H), 7.03 (t, 1H), 6.90 (d, 2H), 4.88 (s, 1H), 3.89 (s, 3H), 2.94 (d, 1H), 2.82 (d, 1H), 2.45 (td, 2H), 2.26 (t, 2H), 1.78 (d, 2H). Dissolve the title compound in Et₂O, add HCl in Et₂O, stir for 1 h and filter to give the HCl salt. MS FAB 374.1 (M+1); elemental analysis for C₂₅H₂₇NO₂·HCl·0.15H₂O: calcd: C 72.77, H 6.91, N 3.39, Cl 8.59; observed: C 72.76, H 7.02, N 3.59, Cl 8.83.

Example 11


Step 1 Alkylate a solution of 1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (0.5g) in CH₃CN using the procedure described in Step 1 of Example 1 to produce desired compound.

Step 2 Alkylate the product from Step 1, 1-phenyl-8-(diphenylmethyl)-1,3,8-triazaspiro[4,5]decan-4-one (0.4 g) with CH₃I using the procedure described in Step 2 of Example 1 to produce the title compound (0.25 g).

^1H NMR (CDCl_3) δ 1.70 (d, 2H), 2.85 (m, 6H), 3.05(s, 3H), 4.50 (s, 1H), 4.72 (s, 2H), 6.95 (t, 1H), 7.05(d 2H), 7.20-7.60 (m, 12H).













- 5 Using the procedures of Examples 1 to 11, employing the appropriate starting material, compounds shown in the following tables are prepared.

Table 1



wherein X^2 is as defined below:

X^2	Physical Data
H	$\text{C}_{24}\text{H}_{25}\text{N}$ FAB 283.3 (100), 167.2 52)
OMe	$\text{C}_{25}\text{H}_{27}\text{NO}$ FAB 358 (80), 167 (70)
OEt	$\text{C}_{26}\text{H}_{29}\text{NO}:\text{HCl}$ FAB 342 (67) 167 (100)
	$\text{C}_{27}\text{H}_{31}\text{NO}$ ESI 386.1 (79), 167 (100)
	$\text{C}_{31}\text{H}_{31}\text{NO}:\text{HCl}$ ESI 434.2 (62), 167 (100)
CN	$\text{C}_{25}\text{H}_{24}\text{N}_2$ FAB 353.2 (53), 275.10 (24).
CHO	$\text{C}_{25}\text{H}_{25}\text{NO}$ CI 356 (28), 167 (100)
CH_2OH	$\text{C}_{25}\text{H}_{27}\text{NO}$ CI 358.1 (37), 167 (100)
	$\text{C}_{32}\text{H}_{33}\text{NO}:\text{HCl}$ FAB 448.1 (46), 167.2 (100)
CH_2OMe	$\text{C}_{25}\text{H}_{27}\text{NO}$ FAB 357.10 (10), 167 (100)
CH_2OEt	$\text{C}_{26}\text{H}_{29}\text{NO}$ CI 373.3 (12), 372(42), 167 (100)

	$C_{30}H_{34}NO$ CI 440.25 (33), 439.2 (100), 167.2 (89)
CH_2NH_2	$C_{25}H_{28}N_2 \cdot 2HCl$ ESI 357.10 (37), 167 (100)
$CH_2NHCOCH_3$	$C_{27}H_{30}N_2O$ ESI 399.1 (53), 167.0 (100)
	$C_{32}H_{32}N_2O$ FAB 462.1(15), 461.1(41), 393 (8)
	$C_{32}H_{34}N_2 \cdot HCl$ ESI 447.1 (100), 281.1 (29)
	$C_{33}H_{32}N_2F_3 \cdot HCl$ ESI 515(100), 349.10 (33), 167 (49)
$CH_2NHCH_2CH_3$	$C_{27}H_{32}N_2 \cdot HCl$ ESI 385.1(100), 219.10 (26), 167 (76)
	$C_{29}H_{36}N_2O \cdot HCl$ CI 429 (53), 351 (100) 327 (13), 167 (34)
	$C_{28}H_{32}N_2O_2$ CI 429 (100), 351 (9), 261 (11), 167 (81)
	$C_{28}H_{34}N_2O \cdot HCl$ CI 415(100), 327 (33), 167 (65)
	$C_{31}H_{39}N_3O \cdot HCl$ ESI 470 (100), 304 (51), 259 (16), 167 (46)
	$C_{31}H_{41}N_3 \cdot HCl$ ESI 456 (100), 290 (11), 167 (11)
	$C_{30}H_{30}N_2O_2$ ESI 451(100), 283 (8), 167 (94)
	$C_{34}H_{43}N_3O \cdot HCl$ ESI 510 (88), 344 (73), 167 (100)
	$C_{32}H_{41}N_3 \cdot HCl$ ESI 468 (98), 302 (22), 167 (100)

























	C ₃₁ H ₃₁ N ₃ O:HCl CI 462(100), 384 (4), 167 (45)
	C ₃₀ H ₃₂ N ₂ O:Cl ESI 437 (100), 271 (11), 167 (41)
	C ₃₀ H ₃₂ N ₂ O:HCl ESI 437 (87), 271 (7), 167 (100)
	C ₃₀ H ₃₂ N ₂ S:HCl ESI 453 (92), 167 (100)
	C ₃₀ H ₃₂ N ₂ S:HCl ESI 453 (100), 287 (6), 167 (78)
	C ₃₂ H ₃₆ N ₂ S:HCl ESI 481 (69), 340 (5), 167 (100)
	C ₂₉ H ₃₆ N ₂ S:HCl ESI 445 (100), 399 (3), 279 (11), 167 (84)
	C ₂₉ H ₃₃ N ₂ F ₃ :HCl ESI 467 (69), 167 (100)
CH ₂ NMe ₂	C ₂₇ H ₃₂ N ₂ :HCl FAB 385.3 (100), 219.2 (6), 162.2 (77)
NH ₂	C ₂₄ H ₂₆ N ₂ :HCl ESI 343 (48), 326 (70), 167 (100)
NH(CH ₂) ₃ NEt ₂	C ₃₁ H ₄₁ N ₃ :HCl ESI 456 (72), 326 (74), 167 (100)
	C ₂₉ H ₃₀ N ₂ O:HCl CI 423 (60), 326 (100), 167 (74)
	C ₃₁ H ₃₉ N ₃ :HCl ESI 454(76), 326 (60), 167 (100)
	C ₂₉ H ₃₀ N ₂ S:HCl FAB 439 (90), 326 (25), 167 (100)
NHMe	C ₂₅ H ₂₈ N ₂ :HCl ESI 357 (20), 326 (87), 167 (100)
NMe ₂	C ₂₆ H ₃₀ N ₂ :HCl ESI 371 (11), 326 (81), 167 (100)

Table 2

wherein X¹ is as defined below

X ¹	Physical Data
	C ₂₄ H ₂₅ NO FAB 343.1 (13), 342.1 (26)
	C ₂₄ H ₂₄ BrNO ESI 424 (20) 422 (18) 167-2 (92)
	C ₂₄ H ₂₄ NOCl CI 363 (43), 362 (22), 167.20 (100)
	C ₂₄ H ₂₄ FNO 361 (22), 167.2 (75)
Benzyl	C ₂₅ H ₂₇ NO CI 358.1 (62), 167 (78)
n-Propyl-phenyl	C ₂₇ H ₃₁ NO:HCl FAB 386.1 (46), 167 (100)
	C ₂₅ H ₂₃ NOF ₃ Cl EI 369 (3), 368 (14), 167 (100)
	C ₂₅ H ₂₄ F ₃ NO FAB 413(31), 412 (57), 167 (100)
	C ₂₅ H ₂₇ NO ₂ CI 374.45(M+1), 266.30 (39%), 167.25 (100%)
	C ₂₆ H ₃₀ N ₂ O FAB 387 (86%), 369 (22%)
	C ₂₅ H ₂₆ NOF FAB 376.2 (68%), 375.2 (32%). 358.20 (6)
	C ₂₅ H ₂₇ NO ₂ CI 374.45 (58%), 375.45 (27), 356.35 (29)
	C ₂₄ H ₂₄ ClNO CI 378.35 (31%), 377.35 (18%), 360.30 (22)

	C ₂₅ H ₂₇ NO CI 358.35 (68), 357.35 (38), 340.35 (47), 167.25 (100)
	C ₂₄ H ₂₃ F ₂ NO CI 380.35(28%), 379.35 (22), 362.35 (23), 167.25 (100)
	C ₂₅ H ₂₇ NO CI 358.35 (63), 357.35 (43), 340.35 (53), 167.25 (100)
	C ₂₅ H ₂₇ NO CI 358.35 (49), 357.35 (41), 340.35 (35), 167.25 (100)
	C ₂₄ H ₂₄ FNO CI 362.35 (41), 361.35 (218), 344.35 (39), 167.25 (100)
	C ₂₆ H ₂₅ NO FAB 368(37), 367 (38), 366(100), 290 (41)
	C ₂₅ H ₂₇ NSO FAB 375 (10), 374.20 (40), 306.7 (13)
	C ₂₅ H ₂₇ NSO FAB 390 (22), 389(27), 388 (100), 312 (48)
	C ₂₄ H ₂₃ NOF ₂ 380.2 (11), 379.2 (16), 378.2 (31)
	C ₂₆ H ₂₉ NO CI 373.45 (22), 372.40 (82), 354.35 (60), 167.25 (100)
	C ₂₄ H ₃₁ NO FAB 350.3 (4), 349.3 (7), 348 917)
n Hexyl	C ₂₄ H ₃₃ NO FAB 352 (85), 274 (189)
n propyl	C ₂₇ H ₃₁ NO ESI 386 (70), 167 (100)
n butyl	C ₂₈ H ₃₃ NO ESI 400.1 (68), 167 (100)
	C ₂₁ H ₂₅ NO:HCl ESI 308.1 (32), 167.0 (100)












































	C ₂₂ H ₂₃ NO ₂ :HCl CI 334.25 (34), 333.25 (26), 316.25 (41), 167.25 (100)
	C ₂₂ H ₂₃ NOS:HCl CI 350.25 (32), 349.35 (24), 332.25 (41), 167.25 (100)
	C ₂₂ H ₂₃ NOS:HCl CI 350.25 (27), 349.35 (18), 332.25 (20), 167.25 (100)
	C ₂₃ H ₂₄ N ₂ O:HCl ESI 345.1(68), 167 (100)
	C ₂₂ H ₂₃ NO ₂ CI 334.25(37), 333.25 (24), 316.25 (31), 167.25 (100)
	C ₂₅ H ₂₄ N ₂ O:HCl FAB 369.3 (3), 368.3 (6), 367.3 (13)
	C ₂₁ H ₂₇ NO:HCl CI 310.40 (38), 309.40 (25), 292.40 (33), 167.25 (100)
	C ₂₄ H ₂₄ NOF:HCl FAB 362.1 (100), 232.1 (11)
	C ₂₂ H ₂₉ NO:HCl FAB 324.30(100)
	C ₂₁ H ₂₅ NO:HCl CI 308.2 (64), 307.2 (30), 290.2 (57), 167.25 (100)
	C ₂₃ H ₂₅ NOS:HCl CI 364.15 (69), 346.15 (71), 167.25 (100)
	C ₂₁ H ₂₂ N ₂ SO:HCl CI 351.1 (52), 350.1 (8), 266.15 (12), 167.2 (100)
	C ₂₇ H ₂₈ N ₂ O:HCl FAB 397.2 (80), 167.2 (100)
	C ₂₅ H ₂₈ N ₂ O:HCl ESI 373.1 (28), 167 (100)
	C ₂₅ H ₂₇ NO ₂ :HCl ESI 374.1 (43), 167 (100)

Table 3



wherein Z¹ and Z² are as defined below:

Z ¹	Z ²	Physical Data
		C ₂₄ H ₂₄ NOCl CI 380 (30), 378.1 (100), 201 (100)
		C ₂₄ H ₂₃ NOF ₂ CI 380.15 (79), 379.15 (47), 362.05 (100)
		C ₂₃ H ₂₄ N ₂ O:HCl ESI 345.1(69), 327.1 (49), 168 (100)
		C ₂₃ H ₂₄ N ₂ O:HCl ESI 345.1 (58), 168 (100)
		C ₂₅ H ₂₇ NO:HCl CI 358.20 (60), 340.20 (51), 181.25 (100)
		C ₂₄ H ₂₄ NOBr:HCl ESI 424.1 (17), 422 (17), 247.1 (100), 245.1 (99)
		C ₂₅ H ₂₇ NO:HCl ESI 358.1(32.70), 181 (100)
		C ₂₄ H ₂₄ NOCl:HCl CI 380.10 (30), 378.15 (100)
		C ₂₆ H ₂₉ NO:HCl ESI 372.1 (24), 195.1 (100)
		C ₂₅ H ₂₇ NO:HCl ESI 358.1 (48%), 181.1 (100)
		C ₂₅ H ₂₄ ONF ₃ :HCl ESI 412.1 (56), 235 (100)
		C ₂₅ H ₂₄ ONF ₃ :HCl ESI 412.1 (73), 235.1 (100)

		$C_{26}H_{29}NO:HCl$ ESI 372.1 (39), 195.1 (100)
		$C_{24}H_{24}NOBr:HCl$ ESI 424.10 (48), 422.1(47), 245.1 (100)
		$C_{22}H_{23}NOS:HCl$ ESI 350.1 (31), 173 (100)
		$C_{25}H_{24}ONF_3:HCl$ ESI 412.1 (54), 235.10 (100)
		$C_{24}H_{24}NOF:HCl$ ESI 362.1 (23), 185.1 (100)
		$C_{24}H_{23}NOF_2:HCl$ CI 380.15 (100), 362.15 (89), 203.25 (99)
		$C_{24}H_{23}NOCl_2:HCl$ ESI 416.1 (7), 414 (32), 412 (45), 235.1 (100)
		$C_{25}H_{24}N_2O_2F_2:HCl$ FAB 423.2 (100), 218.0 (18)
		$C_{24}H_{23}NOF_2:HCl$ CI 380.15 (79), 379.15 (45), 362.05 (100)
		$C_{26}H_{29}NO_2:HCl$ FAB 388.3 (100), 266.1 (15)
		$C_{25}H_{27}NO_2:HCl$ FAB 374.1 (100), 197 (73)
		$C_{24}H_{24}NOCl:HCl$ FAB 380.1(27), 378.2 (80), 201.0 (100)
		$C_{25}H_{27}NO:HCl$ ESI 358.1 (15), 181.1 (100)
Methyl		$C_{19}H_{23}NO:HCl$ ESI 282.1 (100), 160.0 (84.5)































Ethyl		C ₂₀ H ₂₅ NO:HCl ESI 296.1 (100), 160.0 (84)
		C ₂₁ H ₂₇ NO:HCl ESI 310.1 (100), 160.1 (52)
		C ₂₂ H ₂₉ NO:HCl ESI 324.1(100), 160.1 (52)
		C ₂₃ H ₃₁ NO:HCl CI 338.3 (100), 266.20 (77), 160.35 (17)
		C ₂₄ H ₃₃ NO:HCl ESI 352.1 (100), 160.0 (41.83)
		C ₂₃ H ₂₉ NO:HCl ESI 336.1 (66.39), 160.0 (63), 159 (100)
		C ₂₃ H ₃₀ N ₂ O ₂ :HCl ESI 367.1 (35), 190 (100)
		C ₂₃ H ₃₁ NO:HCl ESI 338.1 (100), 161.0 (36), 160 (70)















































Table 4









































wherein X¹, X², Z¹ and Z² are as defined below

X ¹	X ²	Z ¹	Z ²	Physical Data
	NH ₂			C ₂₂ H ₃₀ N ₂ :HCl ESI 323(71), 306 (100), 160(31)
				C ₂₇ H ₃₄ N ₂ S:HCl ESI 419 (23), 306 (100)
	CH ₂ NH ₂			C ₂₃ H ₃₂ N ₂ :HCl ESI 337 (96), 174 (100), 160 (19)
				C ₂₈ H ₃₆ N ₂ S:HCl ESI 433 (100), 320 (65), 174 (58)

	NH ₂			C ₂₅ H ₂₈ N ₂ :HCl CI 357 (47), 340 (24), 279 (8), 181(100)
				C ₂₈ H ₃₆ N ₂ S:HCl ESI 433 (100), 320 (42), 174 (77)
				C ₃₀ H ₃₂ N ₂ S:HCl ESI 453 (24), 340(27), 181 (100)
	NH ₂			C ₂₆ H ₃₀ N ₂ :HCl ESI 371 (16) 195 (100)
				C ₃₁ H ₃₄ N ₂ S:HCl ESI 467 (25), 354 (30), 195 (100)
	NH ₂			C ₂₄ H ₂₄ N ₂ Cl ₂ :HCl ESI 413 (18), 411 (26), 396 (39), 394 (51), 237 (69), 235 (100)
	OH			C ₂₆ H ₂₈ BrNO:HCl 450 (12), 195.1 (100)
	OH			C ₂₆ H ₂₈ FNO:HCl ESI 390.1 (9.6), 195.1 (100)
	OH			C ₂₆ H ₂₈ ClNO:HCl 407.1 (5), 195.1 (100) 406.1 (16)
				C ₃₁ H ₃₂ N ₂ OS ESI 481 (25), 195 (100)
				C ₂₈ H ₃₂ N ₂ O CI 413(31), 354 (8), 195 (100)
				C ₂₉ H ₂₈ Cl ₂ N ₂ S:HCl ESI 509 (10), 507 (14), 396 (56), 394 (77), 237 (68), 235 (100)

	OH			C ₂₅ H ₂₆ N ₂ OCl ₂ :HCl ESI 443(42), 441 (56), 425 (31), 235 (100)
				C ₃₀ H ₃₆ N ₂ OS ESI 473 (39), 195 (100)
				C ₃₃ H ₃₄ N ₂ O ESI 475 (41), 195 (100)
				C ₂₉ H ₃₄ N ₂ O ₂ ESI 443(31), 195 (100)
				C ₃₀ H ₃₄ N ₂ O:HCl ESI 439 (17), 195 (100)
				C ₃₄ H ₄₂ N ₂ O:HCl ESI 495 (30), 195 (100)
				C ₃₃ H ₃₆ N ₂ :HCl ESI 461 (17), 354 (28), 195 (100)
				C ₂₆ H ₂₆ N ₂ OCl ₂ ESI 455 (57), 453 (75), 396 (7), 394 (10), 237 (73), 235 (100)
	OH			C ₂₉ H ₃₁ N ₂ O ₃ F ₃ :HCl FAB 497.2 (507), 195.1 (100)
				C ₂₄ H ₃₂ N ₂ O:HCl ESI 365 (100), 219 (31), 160 (23)
				C ₂₇ H ₃₀ N ₂ O:HCl ESI 399 (60), 181 (100)
				C ₂₉ H ₃₄ N ₂ O:HCl ESI 427 (41), 195 (100)

				$C_{30}H_{36}N_2O:HCl$ ESI 441 (47), 195 (100)
				$C_{28}H_{32}N_3O:HCl$ ESI 428 (41), 195 (100)
	OH			$C_{27}H_{30}Cl_2N_2O$ FAB 469.2 (30), 235.1 (100)
	OH			$C_{28}H_{32}Cl_2N_2O_3S$ CI 549.15 (69), 548.15 (37), 547.15 (100)
	OH			$C_{28}H_{32}Cl_2N_2O_3S$ FAB 549 (60), 547.1 (87)
	OH			$C_{27}H_{30}Cl_2N_2O_3S$ FAB 535 (78), 533 (100)
	OH			$C_{26}H_{28}Cl_2N_2O_3S$ FAB 523 (25)
	OH			$C_{30}H_{35}Cl_2N_3O$ FAB 524.40(20), 330.3 (100)
	OH			$C_{36}H_{39}Cl_2N_3O$ FAB 600.5 (50), 330.4 (70)
	OH			$C_{25}H_{27}BrN_2O$ FAB 453.2 (100), 245 (100)
	OH			$C_{25}H_{26}N_2F_2O$ FAB 410.2 (25), 409.2 (100), 203.2 (50)
	OH			$C_{27}H_{32}N_2O$ FAB 401.2 (95), 195 (100)

	OH			$C_{25}H_{26}Cl_2N_2O$ 441.1 (40), 235 (42), 157 (100)
	OH			$C_{25}H_{27}NO_2$ CI 374.25 (52), 356.2 (100), 178.25 (40), 160.25 (57)
	OH			$C_{25}H_{25}NO_3$ FAB 388.23 (100), 210.8 (21), 168.28 (20)
	OH		$-(CH_2)_4CH_3$	$C_{24}H_{34}N_2O$ FAB 368.3 (30), 367.3 (100)
	OH		$-(CH_2)_3CH_3$	$C_{23}H_{32}N_2O$ GAB 353.3 (100)
	OH			$C_{25}H_{26}N_2F_2O$ FAB 410.6 (35), 409.4 (98), 203.1 (65)
	OH			$C_{26}H_{28}Cl_2N_2O$ FAB 457.3 (70), 455.3 (100), 237 (30), 235.1 (52)
	OH	H		$C_{19}H_{23}N_2OCl$ FAB 331.2 (100),
	OH			$C_{27}H_{32}N_2O$ FAB 402.1 (20.46), 401.1 (44.89), 195.1 (100)
	OH			$C_{25}H_{27}ClN_2O$ ES 409.2 (55), 408.2 (45), 407.2 (95)
	OH			$C_{26}H_{30}N_2O$ ES 387 (100)
	OH			$C_{25}H_{25}NO_2$ CI 372.15 (100), 354.15 (38), 195.15 (37)

































































	OH			C ₂₆ H ₂₉ NO ₃ FAB 404.3 (100), 227.1 (70)
	OH	H		C ₂₁ H ₃₄ N ₂ O FAB 331.4 (100), 266.2 (20)
	OH	CH ₃ (CH ₂) ₃ -		C ₂₄ H ₃₄ N ₂ O FAB 367.2 (100)
	OH			C ₂₇ H ₃₂ N ₂ O ES 401.1 (46), 195.1 (100)
	OH			C ₃₁ H ₃₈ N ₂ O ₃ ES 487 (100)
				C ₂₇ H ₂₉ Cl ₂ N ₃ O ESI 484.2 (72), 482.2 (100), 237 (60), 235.0 (65)
				C ₂₆ H ₂₇ Cl ₂ N ₃ O ESI 470.1 (80), 468.1 (100), 235 (78)
				C ₂₆ H ₂₇ Cl ₂ N ₃ O ESI 470.2 (78), 468.2 (90), 237.0 (65), 235 (100)
				C ₂₉ H ₃₅ N ₃ O ESI 442.3 (100)
	OH			C ₂₅ H ₂₆ N ₂ OBr ₂ ESI 533 (55), 531 (100), 324.8 (30)
















Table 5



wherein R¹¹, Z¹ and Z² are as defined in the following table, wherein Ac
 5 is acetyl, Me is methyl and Et is ethyl::


R11	CH(Z ¹)(Z ²)	Physical Data
H	Benzhydryl	
	Benzhydryl	C ₃₂ H ₃₇ N ₃ O:HCl CI 480 (100), 167.25 (22)
	Benzhydryl	C ₂₉ H ₃₁ N ₃ O ₃ :HCl CI 470.15 (100), 167.25 (25)
	Benzhydryl	C ₂₉ H ₃₁ N ₃ O:HCl CI 438.20 (100), 167.25 (29)
	Benzhydryl	C ₃₀ H ₃₃ N ₃ O:HCl FAB 452.3 (100), 167.0 (92)
	Benzhydryl	C ₂₉ H ₃₃ N ₃ O:HCl CI 440.20 (100), 167.25 (22)
Me	Benzhydryl	C ₂₆ H ₂₇ N ₃ O:HCl CI 398.15 (100), 167.25 (39)
Ethyl	Benzhydryl	C ₂₇ H ₂₉ N ₃ O:HCl CI 412.15 (100), 167.25 (32)
n propyl	Benzhydryl	C ₂₈ H ₃₁ N ₃ O:HCl ESI 426.1(14), 167 (100)
n butyl	Benzhydryl	C ₂₉ H ₃₃ N ₃ O:HCl ESI 440.10 (100), 167.10 (33)
isopropyl	Benzhydryl	C ₂₈ H ₃₁ N ₃ O:HCl ESI 446.10 (28), 167. (100)
	Benzhydryl	C ₂₈ H ₃₁ N ₃ O ₂ :HCl ESI 442.10 (15), 167. (100)
	Benzhydryl	C ₂₇ H ₂₉ N ₃ O ₂ :HCl FAB 428.3 (65), 232.1 (57)
H		C ₂₃ H ₂₉ N ₃ O:HCl ESI 364.1 (58), 218.1 (100)
		C ₂₅ H ₃₃ N ₃ O ₂ :HCl ESI 408.1 (93), 262.1 (100)
n pentyl	Benzhydryl	C ₃₀ H ₃₅ N ₃ O :HCl ESI 454.1 (46), 167.1 (100)
n-hexyl	Benzhydryl	C ₃₁ H ₃₇ N ₃ O:HCl ESI 468.1 (26), 167 (100)

	Benzhydryl	$C_{28}H_{31}N_3O_2 \cdot HCl$ ESI 442.10 (15), 167 (100)
		$C_{31}H_{35}N_3O \cdot HCl$ ESI 466.1 (44), 181.1 (100)
		$C_{29}H_{33}N_3O_2 \cdot HCl$ ESI 456.1 (48), 181.10(100)
H		$C_{24}H_{31}N_3O \cdot HCl$ CI 378.25 (100), 306.20 (22), 218.20 (24)
H		$C_{26}H_{27}N_3O \cdot HCl$ ESI 398.10 (44), 181.1 (100)
		$C_{27}H_{33}N_3O \cdot HCl$ ESI 416.10(36), 286.1 (39)
		$C_{30}H_{31}N_3OCl_2 \cdot HCl$ ESI 522.1 (79), 521.1 (48), 520 (100)
	Benzhydryl	$C_{30}H_{34}N_2O \cdot HCl$ CI 439.25 (100), 168.30 (20)
H		$C_{27}H_{29}N_3O \cdot HCl$ CI 412.20(32), 218.20 (42), 195.35 (100)
	Benzhydryl	$C_{29}H_{31}N_3O_3 \cdot HCl$ ESI 470.1 (100), 167.1 (77.40)
H		$C_{25}H_{23}N_3Cl_2O \cdot HCl$ ESI 452.1 (100), 235 (85)
		$C_{30}H_{33}N_3O_2Cl_2 \cdot HCl$ ESI 525.1 (39), 524.1 (82), 522 (100)
		$C_{28}H_{29}N_3OCl_2 \cdot HCl$ ESI 511.1 (46), 510 (100), 514 (20), 513.1 (33.50)
		$C_{32}H_{39}N_3O \cdot HCl$ ESI 482.1 (48), 195.1 (100)

		$C_{30}H_{35}N_3O_2:HCl$ ESI 471.1 (13), 470.1 (30), 195.1 (100)
H		$C_{25}H_{24}N_3OCl:HCl$ FAB 420.2 (35), 418.2 (100), 201.0 (75)
H		$C_{25}H_{24}N_3OF:HCl$ Elemental Analysis C: 68.12; H: 5.83; N: 9.48; Cl: 8.21; F: 4.59
	Benzhydryl	$C_{28}H_{32}N_4O:HCl$ ESI 442.1 (39), 441.1 (92), 167 (100)
	Benzhydryl	$C_{29}H_{34}N_4O:HCl$ ESI 455.1 (100), 290.1 (14), 289.1 (57.88), 167 (94)
	Benzhydryl	$C_{27}H_{30}N_4O:HCl$ ESI 428.1 (42), 427.1(97), 167 (100)
	Benzhydryl	$C_{30}H_{36}N_4O.HCl$ ESI 470.1 (48), 469 (100), 303 (93), 167 (82.75)
	Benzhydryl	$C_{29}H_{34}N_4O:HCl$ ESI 457.1(13), 456 (57), 455.1 (100), 167 (72)
	Benzhydryl	$C_{28}H_{29}N_3O_3$ FAB 456.2 (78), 167.0 (100)
		$C_{22}H_{23}Cl_2N_3O_3$ FAB 450.1 (27), 448.0 (100)
H		$C_{24}H_{31}N_3O$ FAB 378.4 (100), 218.2 (30)
	Benzhydryl	$C_{31}H_{35}N_3O_3$ 498.2 (100), 167.1 (90)
	Benzhydryl	$C_{29}H_{31}N_3O_3$ ESI 470.1 (100), 167.1 (55)















		$C_{23}H_{27}Cl_2N_3O$ ESI 434.1 (80), 432.1 (100)
		$C_{22}H_{25}Cl_2N_3O_2$ ESI 436.1 (58), 434.1 (100)
		$C_{23}H_{27}Cl_2N_3O$ ESI 434.1 (35), 432.1 (100)
		$C_{24}H_{27}Cl_2N_3O$ ESI 446.1 (77), 444.1 (100)
		$C_{21}H_{22}Cl_2N_4O_2$ FAB 435.1 (78), 433.1 (100)























Table 6
















































wherein R_{11} , Z^1 and Z^2 are as defined in the following table:



























R_{11}	$CH(Z^1)(Z^2)$	Physical Data
H	Benzhydryl	
	Benzhydryl	$C_{29}H_{33}N_3O$ ESI: 440 (100) 167 (80)
	Benzhydryl	$C_{29}H_{31}N_3O$ ESI: 438 (100) 167 (99)
	Benzhydryl	$C_{30}H_{35}N_3O$ ESI: 454 (100) 167 (94)
	Benzhydryl	$C_{29}H_{29}N_3O$ ESI: 436 (99) 167 (100)
CH ₃	Benzhydryl	$C_{27}H_{29}N_3O$ FAB: 412 (100)
	Benzhydryl	$C_{28}H_{31}N_3O$ FAB: 426 (100)

























	Benzhydryl	$C_{30}H_{33}N_3O_3$ FAB: 484 (7) 261 (14) 167 (100)
	Benzhydryl	$C_{30}H_{33}N_3O$ ESI: 452 (100) 167 (60)
	Benzhydryl	$C_{33}H_{39}N_3O$ ESI: 494 (100) 167 (30)
	Benzhydryl	$C_{31}H_{35}N_3O \cdot HCl$ FAB: 466 (100)
	Benzhydryl	$C_{30}H_{33}N_3O_3 \cdot HCl$ FAB: 484 (100) 167 (41)
	Benzhydryl	$C_{33}H_{38}N_4O_2 \cdot HCl$ FAB: 523 (100)
H		$C_{26}H_{25}N_3F_2O \cdot HCl$ ESI: 434 (29) 203 (100)
H		$C_{26}H_{25}N_3F_2O \cdot HCl$ Cl: 434 (100)
H		$C_{26}H_{26}N_3ClO \cdot HCl$ ESI: 432 (60) 201 (100)
	Benzhydryl	$C_{29}H_{33}N_3O \cdot HCl$ ESI: 440 (100) 167 (89)
	Benzhydryl	$C_{33}H_{37}N_3O_2 \cdot HCl$ ESI: 508 (100) 167 (35)
H		$C_{24}H_{30}N_3ClO \cdot HCl$ ESI: 412 (100) 232 (92)
H		$C_{24}H_{31}N_3O \cdot HCl$ ESI: 378 (100) 232 (82)
H		$C_{21}H_{24}N_3ClO \cdot HCl$ ESI: 370 (86) 265 (100)

H		$C_{24}H_{30}N_3FO \cdot HCl$ ESI: 396 (31) 232 (100)
H		$C_{24}H_{30}N_3BrO \cdot HCl$ ESI: 456 (39) 232 (100)
H		$C_{25}H_{33}N_3O \cdot HCl$ ESI: 392 (73) 232 (100)
H		$C_{25}H_{31}N_3O \cdot HCl$ FAB: 390 (100)
		$C_{28}H_{39}N_3O \cdot HCl$ ESI: 434 (68) 288 (100)
		$C_{31}H_{43}N_3O \cdot HCl$ ESI: 474 (90) 328 (100)
		$C_{27}H_{37}N_3O \cdot HCl$ ESI: 420 (81) 274 (100)
H		$C_{27}H_{29}N_3O \cdot HCl$ FAB: 412 (25) 181 (100)
		$C_{29}H_{41}N_3O \cdot HCl$ ESI: 448 (97) 288 (100)
		$C_{27}H_{37}N_3O \cdot HCl$ ESI: 420 (62) 274 (100)
		$C_{28}H_{39}N_3O \cdot HCl$ ESI: 434 (66) 274 (100)
H		$C_{25}H_{33}N_3O \cdot HCl$ ESI: 392 (59) 232 (100)
		$C_{31}H_{37}N_3O \cdot HCl$ ESI: 468 (100) 322 (92)
		$C_{28}H_{39}N_3O \cdot HCl$ ESI: 434 (100) 274 (86)

H		$C_{22}H_{25}N_3O_3 \cdot HCl$ CI: 380 (100)
		$C_{32}H_{39}N_3O \cdot HCl$ ESI: 482 (100) 322 (78)
H		$C_{21}H_{25}N_3O_2 \cdot HCl$ FAB: 352 (100)
		$C_{33}H_{41}N_3O \cdot HCl$ FAB: 496 (100)
H		$C_{28}H_{31}N_3O \cdot HCl$ ESI: 426 (19) 195 (100)
H		$C_{26}H_{26}N_3Cl_2O \cdot HCl$ ESI: 466 (79) 235 (100)
H		$C_{25}H_{32}N_4O_2 \cdot HCl$ ESI: 421 (40) 190 (100)
H		$C_{26}H_{26}N_3FO \cdot HCl$ FAB: 416 (100)
H		$C_{26}H_{25}N_3Cl_2O \cdot HCl$ ESI: 466 (100) 235 (60)
H		$C_{26}H_{26}N_3ClO \cdot HCl$ ESI: 432 (48) 201 (100)
H		$C_{26}H_{26}N_3F_2O \cdot HCl$ ESI: 434 (69) 203 (100)
		$C_{29}H_{37}N_3O \cdot HCl$ ESI: 444 (52) 326 (100)
		$C_{27}H_{33}N_3O \cdot HCl$ ESI: 416 (33) 300 (100)
























		$C_{28}H_{29}N_3Cl_2O_2 \cdot HCl$ ESI: 510 (100)
		$C_{31}H_{33}N_3Cl_2O_2 \cdot HCl$ ESI: 550 (100)
		$C_{30}H_{33}N_3Cl_2O \cdot HCl$ ESI: 522 (100)
		$C_{31}H_{35}N_3Cl_2O \cdot HCl$ ESI: 536 (100)
		$C_{29}H_{29}N_3Cl_2O_3 \cdot HCl$ FAB: 538 (100)
		$C_{29}H_{31}N_3Cl_2O_2 \cdot HCl$ ESI: 524 (100)
		$C_{32}H_{36}N_4Cl_2O \cdot HCl$ FAB: 563 (100) 235 (55)
		$C_{27}H_{37}N_3O_2 \cdot HCl$ FAB: 436 (100)
		$C_{24}H_{31}N_3O_3 \cdot HCl$ FAB: 410 (100)
		$C_{25}H_{33}N_3O_2 \cdot HCl$ FAB: 408 (100)
		$C_{26}H_{35}N_3O_2 \cdot HCl$ FAB: 422 (100)
		$C_{29}H_{32}N_4Cl_2O \cdot 2HCl$ FAB: 523 (100)
		$C_{31}H_{36}N_4Cl_2O \cdot 2HCl$ FAB: 551 (100)
		$C_{30}H_{34}N_4Cl_2O \cdot 2HCl$ FAB: 537 (100)

		$C_{30}H_{34}N_4Cl_2O \cdot 2HCl$ FAB: 537 (100)
		$C_{29}H_{38}N_4O \cdot 2HCl$ FAB: 459 (100)
		$C_{33}H_{38}N_4Cl_2O \cdot 2HCl$ ESI: 577 (56) 343 (100)
		$C_{33}H_{38}Cl_2N_4O$ ESI 577 (100), 343 (45)
		$C_{33}H_{38}Cl_2N_4O$ ESI 577 (100), 343 (45)
		$C_{34}H_{40}Cl_2N_4O$ ESI 591 (100), 357 (81)
		$C_{31}H_{44}N_4O$ ESI 487 (100), 327 (51)
		$C_{33}H_{39}Cl_2N_5O$ ESI 592 (100), 358 (71), 235 (64)
		$C_{31}H_{34}Cl_2N_4O$ ESI 549 (100), 315 (52)
		$C_{31}H_{42}N_4O$ ESI 487 (100), 329 (85)
		$C_{31}H_{44}N_4O$ ESI 489 (100), 331 (99)
		$C_{33}H_{38}Cl_2N_4O_2$ ESI 593 (100), 359 (45), 297 (45)
		$C_{34}H_{40}Cl_2N_4O$ ESI 591 (100), 357 (82), 235 (99)

		$C_{34}H_{39}Cl_2N_5O_2$ ESI 620 (100), 386 (12), 235 (28)
		$C_{32}H_{38}Cl_2N_4O$ ESI 565 (100), 331 (56), 235 (52)
		$C_{32}H_{36}Cl_2N_4O_2$ ESI 579 (100), 345 (51), 235 (76)
		$C_{33}H_{38}Cl_2N_4O_2$ ESI 593 (100), 359 (63), 235 (90)
		$C_{35}H_{42}Cl_2N_4O$ ESI 605 (100), 371 (83)
		$C_{37}H_{44}Cl_2N_4O_3$ FAB 663 (100), 234 (42)
		$C_{25}H_{32}Cl_2N_4O_2$ ESI 491 (100), 333 (29)
		$C_{26}H_{32}Cl_2N_4O$ ESI 487 (100), 319 (31)
		$C_{26}H_{34}Cl_2N_4O$ ESI 489 (100), 331 (18)
		$C_{32}H_{46}N_4O_2$ ESI 519 (91), 361 (100)
		$C_{25}H_{32}N_4Cl_2O$ ESI 475 (100), 317 (24), 159 (69)
		$C_{28}H_{38}N_4O$ FAB 447.3 (100), 289.2 (25), 242.2 (36)

		$C_{29}H_{40}N_4O$ FAB 461.2 (100), 303.2 (20)
		$C_{31}H_{42}N_4O_2$ ESI 503.1 (100), 345.1 (95)
		$C_{30}H_{42}N_4O$ ESI 475.1 (99), 317.1 (100)
		$C_{30}H_{42}N_4O$ ESI 475.1 (89), 317.1 (100)
		$C_{33}H_{48}N_4O_2$ ESI 519.1 (95), 361.1 (100) 256.1 (12)
		$C_{29}H_{40}N_4O_2$ ESI 477.1 (100), 319.1 (100)
		$C_{31}H_{42}N_4O$ ESI 487.10 (100), 329.1 (88)
		$C_{28}H_{38}N_4O$ FAB 447 (100), 391 (30), 317 (20)
		$C_{29}H_{41}N_5O$ FAB 476 (100), 346 (40)
		$C_{29}H_{40}N_4O$ FAB 461 (100), 391 (40), 167 (22)
		$C_{28}H_{38}N_4O$ FAB 447 (100), 391 (60)
		$C_{31}H_{42}N_4O$ ESI 487.1 (100), 329.1 (86)

		$C_{30}H_{42}N_4O_2$ ESI 491.1 (63), 333.10 (100)
		$C_{34}H_{48}N_4O$ ESI 529.1 (79), 371.1 (100)
		$C_{31}H_{45}N_5O$ ESI 504.1 (99), 358.1 (100)
		$C_{32}H_{45}N_5O$ ESI 516.1 (92), 358.1 (100), 251.1 (28)
		$C_{25}H_{32}Cl_2N_4O$ ESI 475 (100), 317 (16)
		$C_{24}H_{30}Cl_2N_4O$ ESI 461 (100), 303 (25)
		$C_{23}H_{28}Cl_2N_4O$ ESI 447 (100), 224 (64)
		$C_{26}H_{34}Cl_2N_4O$ ESI 489 (100), 331 (33)
		$C_{27}H_{25}F_4N_3O$ ESI 484 (100)
		$C_{26}H_{32}Cl_2N_4O$ ESI 487 (100), 433 (39)
		$C_{26}H_{32}Cl_2N_4O$ ESI 487 (100), 433 (46)
		$C_{31}H_{44}N_4O$ ESI 489.1 (100), 331.1 (68)

		$C_{30}H_{40}N_4O$ ESI 473.1 (100), 315.1 (55)
		$C_{32}H_{46}N_4O$ ESI 503.1 (100), 345.1 (834)
		$C_{33}H_{46}N_4O$ ESI 515.1 (73), 357.1 (100), 258.1 (9)
		$C_{32}H_{40}N_4OS$ ESI 433.1 (22), 371.1 (83)
		$C_{32}H_{44}N_4O$ ESI 501.1 (80), 343.1 (100), 251.1 (7), 159.1 (69)
		$C_{32}H_{40}N_4O_2$ ESI 513.1 (87), 433.1 (32), 355.1 (100), 275.1 (12)
		$C_{34}H_{42}N_4O$ ESI 523.1 (91), 365.1 (100)
		$C_{32}H_{38}Cl_2N_4O$ ESI 565 (100), 331 (56), 235 (52)
H		$C_{26}H_{27}N_3O$ ESI 398 (100), 397 (4)
		$C_{26}H_{34}FN_4O$ ESI 457 (92), 229 (100)
		$C_{29}H_{40}N_4O$ ESI 461 (99), 231 (100)
		$C_{30}H_{42}N_4O_2$ ESI 491.1 (90), 331.1 (65), 61 (100)

		$C_{31}H_{43}ClN_4O$ ESI 525.1 (42), 524.1 (53), 523.1 (65), 331.1 (60), 193.1 (100)
		$C_{28}H_{38}N_4O_2$ ESI 463 (100), 331 (38)
		$C_{29}H_{40}N_4O_3$ ESI 494 (100), 247 (95)
		$C_{26}H_{34}Cl_2N_4O$ ESI 491(86) 489 (100), 245 (72)
		$C_{28}H_{38}N_4O$ ESI 447 (88), 224 (100)
		$C_{26}H_{35}ClN_4O$ ESI 455 (100), 228 (85)
		$C_{26}H_{35}ClN_4O$ ESI 455 (100), 228 (60)
		$C_{24}H_{31}ClN_4O$ ESI 427 (100), 303 (10), 214 (48)
		$C_{23}H_{29}BrN_4O$ ESI 459 (99), 457 (100), 230 (45)
		$C_{26}H_{35}BrN_4O$ FAB 501 (99), 499 (100), 235 (40)
		$C_{26}H_{35}BrN_4O$ FAB 501 (99), 499 (100), 171 (28)
		$C_{26}H_{35}BrN_4O$ FAB 499(99), 497 (100), 171 (20)

		$C_{26}H_{33}FN_4O$ FAB 439 (100), 220 (7)
		$C_{26}H_{35}FN_4O$ FAB 439 (100), 220 (40)
H		$C_{21}H_{25}N_3O$ FAB 336 (100), 171 (100)
		$C_{23}H_{29}FN_4O$ FAB 397 (100), 242 (100)
		$C_{24}H_{31}FN_4O$ FAB 411 (100), 242 (90)
H		$C_{19}H_{27}N_3O$ FAB 314 (100), 247 (7)
		$C_{29}H_{39}FN_4O$ ESI 479.1(100), 424.1 (31), 331.1 (43), 203.1 (61)
		$C_{29}H_{39}FN_4O$ ESI 479.1(100), 424.1 (11), 331.1 (39), 203.1 (38)
		$C_{29}H_{39}ClN_4O$ ESI 495.1 (70), 345.1 (37), 65.0 (100)
H		$C_{24}H_{25}N_3O$ ESI 372.1 (100), 200.1 (4)
		$C_{30}H_{38}N_4O$ ESI 471.1 (100), 331.1 (36)
H		$C_{20}H_{29}N_3O$ ESI 328 (100)
H		$C_{21}H_{31}N_3O$ ESI 342 (100)




































H		$C_{22}H_{33}N_3O$ ESI 356.1 (100), 171.1 (5)
		$C_{24}H_{37}N_3O$ ESI 370.1 (100), 247.1 (20)

Table 7
compounds of the formulas shown, wherein Ph is phenyl

Compound	Physical Data
	$C_{25}H_{27}NO.HCl$ ESI 358.1 (44.50), 167.0 (100)
	$C_{25}H_{27}NO.HCl$ FAB 358.2 (100), 232.1 (23.70)
	$C_{27}H_{29}NO.HCl$ CI 348.20 (58), 366.25 (48)
	$C_{26}H_{27}NO.HCl$ FAB 370.1 (100), 167.0 (100)
	$C_{28}H_{31}NO.HCl$ FAB 398.1 (100), 195.1 (98)
	$C_{26}H_{25}NOCl_2.HCl$ FAB 440.1 (65), 438.0 (100), 236.9 (38), 234.9 (60)
	$C_{25}H_{23}NO_2.HCl$ FAB 370.2 (100), 292.2 (18)

	$C_{25}H_{25}NO \cdot HCl$ ESI 356.1 (14.77), 168 (20.98), 167 (100)
	$C_{26}H_{27}N \cdot HCl$ ESI 354.1 (55.06), 167.1 (100),
	$C_{26}H_{25}N \cdot HCl$ ESI 352.1 (41.94), 167.1 (100)
	$C_{25}H_{25}NO_2 \cdot HCl$ ESI 372.1 (15.42), 167 (100)
	$C_{26}H_{27}NO_2 \cdot HCl$ CI 386.10 (73), 354.05 (88), 167.25 (100),
	$C_{25}H_{24}N_3Cl \cdot HCl$ CI 402 (55), 366.20 (77), 250.15 (34), 167.25 (100),
	$C_{24}H_{27}N_3O \cdot HCl$ CI 398.05 (100), 232.10 (19), 167.25 (74),
	$C_{25}H_{26}N_2$ CI 356.2 (26) 355.2 (100), 167(28)
	$C_{26}H_{25}N_3O_2 \cdot HCl$ ESI 412 (20), 167.1 (100)
	$C_{26}H_{25}F_2NO$ ESI 406.1 (100), 203.1 (89.11)

	$C_{26}H_{26}ClNO$ ESI 406.1 (34.35), 404.10 (81.42), 201.10 (100)
	$C_{27}H_{29}NO$ ESI 384.1 (54.52), 181 (100)
	$C_{27}H_{28}Cl_2N_2O$ ESI 399.1 (13.87), 398.1 (56.98), 397.1 (100)
	$C_{26}H_{26}FNO$ ESI 388.2 (90), 185.0 (100)
	$C_{29}H_{34}N_2O$ ESI 429.1 (8.33), 428.10 (36.55), 427.1 (74.28)
	$C_{24}H_{31}NO$ FAB 350.4 (100), 204.3 (18)
	$C_{25}H_{33}NO$ FAB 364.40 (100), 204.3 (20)

	$C_{27}H_{28}F_2N_2O$ FAB 435.2 (100), 203.1 (55)
	$C_{26}H_{26}BrNO$ FAB 448.1 (100), 247.0 (58), 166.1 (38)
	$C_{26}H_{25}Br_2NO$ ESI 528 (100), 325.1 (54.35)
	$C_{27}H_{28}Br_2N_2O$ FAB 560 (20), 557 (100), 324.8 (60)
	$C_{27}H_{27}NO_3$ CI 414.20 (100), 396.20 (34), 211.15 (47), 186.15 (30)
	$C_{19}H_{19}N_3O$ ESI 306.1 (100)
	$C_{21}H_{29}N_3O$ ESI 341.1 (30.27), 340.1 (100)
	$C_{23}H_{33}N_3O$ ESI 369.1 (39.66), 368.1 (100)











	$C_{28}H_{31}NO_3$ ESI 430.1 (100), 204.1 (52.46)
	$C_{28}H_{27}NO_3$ FAB 426.3 (100), 225.0 (18), 195 (18)
	$C_{30}H_{35}NO$ ESI 426.1 (100), 408 (11), 223.0 (43)
	$C_{28}H_{31}NO_3$ ESI 430.1 (100), 412.1 (11.0), 227.0 (24.2)
	$C_{25}H_{33}NO$ ESI 364.10 (100), 346 (7)
	$C_{21}H_{23}NO_3$ FAB 338.1 (100)
	$C_{21}H_{21}F_4NO_2$ ESI 396.1 (100)
	$C_{22}H_{27}NO_3$ CI 354 (100), 336 (78)
	$C_{21}H_{21}F_4NO$ ESI 380.1 (100)

Table 8



wherein Z^1 and Z^2 are as defined in the following table:

Z^1	Z^2	Physical Data
		$C_{25}H_{24}N_2O \cdot HCl$ FAB 369.2 (75), 167.1 (100)
		$C_{27}H_{28}N_2O \cdot HCl$ FAB 397.2 (40), 195.1 (100)
		$C_{26}H_{26}N_2O \cdot HCl$ ESI 383.1 (11.64), 181.1 (100)
		$C_{25}H_{24}N_2Cl_2O \cdot HCl$ ESI 441.1 (11.05), 440.1 (15.61), 439.1 (48.02), 438.1 (23.94), 437.1 (64.05), 235.1 (100)
		$C_{25}H_{22}N_2OF_2 \cdot HCl$ FAB 405.2 (100), 203.1 (76)
		$C_{25}H_{23}ClN_2O \cdot HCl$ FAB 403.1 (100) 201(70)

- 5 Compounds of formulas II to VI can be prepared according to the procedures disclosed in the cited patent specifications.

ASSAYS

Nociceptin binding assay








- 10 CHO cell membrane preparation expressing the ORL-1 receptor (2 mg) was incubated with varying concentrations of [125 I][Tyr 14]nociceptin (3-500 pM) in a buffer containing 50 mM HEPES (pH7.4), 10 mM NaCl, 1mM MgCl $_2$, 2.5 mM CaCl $_2$, 1 mg/ml bovine serum albumin and 0.025% bacitracin. In a number of studies, assays were carried out in buffer 50
- 15 mM tris-HCl (pH 7.4), 1 mg/ml bovine serum alumbin and 0.025%


bacitracin. Samples were incubated for 1h at room temperature (22°C). Radiolabelled ligand bound to the membrane was harvested over GF/B filters presoaked in 0.1% polyethyleneimine using a Brandell cell harvester and washed five times with 5 ml cold distilled water.

- 5 Nonspecific binding was determined in parallel by similar assays performed in the presence of 1 μ M nociceptin. All assay points were performed in duplicates of total and non-specific binding.






Calculations of K_i were made using methods well known in the art.








- For compounds of this invention, K_i values were determined to be
 10 in the range of 0.6 to 3000 nM, with compounds having a K_i value less than 10 nM being preferred. K_i values for representative compounds of the invention are as follows:

Compounds	K_i (nM)
	13
	200
	60
	0.6
	2.3
	77
	18

	3,000
---	-------

Using the procedures described in the European Journal of Pharmacology, 336 (1997), p. 233-242, the agonist activity of compounds of the invention was determined:


Compound	% Stimulation of [³⁵ S]-GTP _γ S binding to human ORL-1 receptor @ 100 nM
	77
	43
	59
	102
	71

	43
	15
	95
	107
	120
	70
	101


EXAMPLE 12

Cough Studies

The effects of nociceptin agonist Compound A (0.3 - 10 mg/kg, p.o.) and Compound B (10 mg/kg, p.o.)



COMPOUND A



COMPOUND B

5 were evaluated in capsaicin-induced cough in the guinea pig according to the methods of Bolser et al. British Journal of Pharmacology (1995) 114, 735-738. This model is a widely used method to evaluate the activity of potential antitussive drugs. Overnight fasted male Hartley guinea pigs
10 (350-450 g, Charles River, Bloomington, MA, USA) were placed in a 12" x 14" transparent chamber. The animals were exposed to aerosolized capsaicin (300 μ M, for 4 min) produced by a jet nebulizer (Puritan Bennett, Lenexa, KS, USA) to elicit the cough reflex. Each guinea pig was exposed only once to capsaicin. The number of coughs were
15 detected by a microphone placed in the chamber and verified by a trained observer. The signal from the microphone was relayed to a polygraph which provided a record of the number of coughs. Either vehicle (methylcellulose 1 ml/kg, p.o.) or Compound A or Compound B were given 2 hours before aerosolized capsaicin. The antitussive activity of
20 baclofen (3 mg/kg, p.o.) was also tested as a positive control. The results are summarized in the bar graph in Fig. 1.

EXAMPLE 13

Respiratory Measurements

25 Studies were performed on male Hartley guinea pigs ranging in weight from 450 to 550 g. The animals were fasted overnight but given water and libitum. The guinea pigs were placed in a whole-body, head-out plethysmograph and a rubber collar was placed over the animal's head to provide an airtight seal between the guinea pig and the plethysmograph. Airflow was measured as a differential pressure across

a wire mesh screen which covered a 1-in hole in the wall of the plethysmograph. The airflow signal was integrated to a signal proportional to volume using a preamplifier circuit and a pulmonary function computer (Buxco Electronics, Sharon, CT., model XA). A head
5 chamber was attached to the plethysmograph and air from a compressed gas source (21%O₂, balance N₂) was circulated through the head chamber for the duration of study. All respiratory measurements were made while the guinea pigs breathed this circulating air.

The volume signal from each animal was fed into a data
10 acquisition/analysis system (Buxco Electronics, model XA) that calculated tidal volume and respiratory rate on a breath-by-breath basis. These signals were visually displayed on a monitor. Tidal volume and respiratory rate were recorded as an average value every minute.

The guinea pigs were allowed to equilibrate in the plethysmograph
15 for 30 min. Baseline measurements were obtained at the end of this 30 min period. The guinea pigs were then removed from the plethysmograph and orally dosed with Compound A from Example 12 (10 mg/kg, p.o.), baclofen (3 mg/kg, p.o.) or a methylcellulose vehicle placebo (2 ml/kg, p.o.). Immediately after dosing, the guinea pigs were placed
20 into the plethysmograph, the head chamber and circulating air were reconnected and respiratory variables were measured at 30, 60, 90 and 120 min post treatment. This study was performed under ACUC protocol #960103.

25 Data Analysis

The data for tidal volume (V_T), respiratory rate (f) and minute volume ($MV = V_T \times f$) were made for the baseline condition and at each time point after the drug or vehicle. The results are expressed as the mean \pm SEM. The results are shown in Figures 2A, 2B and 2C. Fig. 2A
30 shows the change in Tidal Volume, Fig. 2B shows the change in Tidal Volume and Fig. 2C shows the change in frequency of breaths.

We have surprisingly discovered that nociceptin receptor ORL-1 agonists exhibit anti-tussive activity, making them useful for suppressing
35 coughing in mammals. The ORL-1 agonists decrease the severity and

frequency of coughing. The coughing can be chronic, intractable or caused by a transient medical or environmental condition. Non-limiting examples of the causes for coughing are irritants, inflammatory diseases, influenza, asthma and upper respiratory diseases.

- 5 For mammals treated for coughing, the nociceptin receptor ORL-1 agonists may be administered along with one or more additional agents for treating cough, allergy or asthma symptoms selected from antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives,
10 α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists. For example, the ORL-1 agonist can be administered in combination with an expectorant or an antihistamine, or with both an expectorant and an antihistamine. The combination
15 preferably comprises 2 to 4 active agents.

- Non limitative examples of antihistamines include: astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine (also known as SCH-34117),
20 doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, equitazine, mianserin, noberastine, meclizine, norastemizole, picumast, pyrillamine, promethazine, terfenadine, tripeleminamine, temelastine, trimeprazine and triprolidine.

- 25 Non-limitative examples of histamine H₃ receptor antagonists include: thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, UCL-1199 and clozapine. Other compounds can readily be evaluated to determine activity at H₃ receptors by known
30 methods, including the guinea pig brain membrane assay and the guinea pig neuronal ileum contraction assay, both of which are described in U.S. Patent 5,352,707. Another useful assay utilizes rat brain membranes and is described by West et al., "Identification of Two-H₃-Histamine Receptor Subtypes," *Molecular Pharmacology*, Vol. 38, pages
35 610-613 (1990).

The term "leukotriene inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the action or activity of leukotrienes. Non-limitative examples of leukotriene inhibitors include montelukast [R-(E)]-1[[[1-[3-[2-(7-chloro-2-quinoliny)]-ethenyl]phenyl]-3[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid and its sodium salt, described in EP 0 480 717; 1-(((R)-(3-(2-(6,7-difluoro-2-quinoliny)]ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio) methylcyclopropaneacetic acid, and its sodium salt, described in WO 97/28797 and U.S. Patent 5,270,324; 1-(((1(R)-3(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio) methyl)cyclopropaneacetic acid, and its sodium salt, described in WO 97/28797 and U.S. Patent 5,472,964; pranlukast, N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-p-(4-phenylbutoxy) benzamide) described in WO 97/28797 and EP 173,516; 15 zafirlukast, (cyclopentyl-3-[2-methoxy-4-[(o-tolylsulfonyl) carbamoyl]benzyl]-1-methylindole-5-carbamate) described in WO 97/28797 and EP 199,543; and [2-[[2(4-*tert*-butyl-2-thiazolyl)-5-benzofuranyl] oxymethyl]phenyl]acetic acid, described in U.S. Patent 5,296,495 and Japanese patent JP08325265 A.

20 The term "5-lipoxygenase inhibitor" or "5-LO inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the enzymatic action of 5-lipoxygenase. Non-limitative examples of 5-lipoxygenase inhibitors include zileuton, docebenone, piripost, ICI-D2318, and ABT 761.

25 Non-limitative examples of β -adrenergic receptor agonists include: albuterol, bitolterol, isoetharine, mataproterenol, perbuterol, salmeterol, terbutaline, isoproterenol, ephedrine and epinephrine.

A non-limitative example of a xanthine derivative is theophylline.

30 Non-limitative examples of α -adrenergic receptor agonists include arylalkylamines, (e.g., phenylpropanolamine and pseudephedrine), imidazoles (e.g., naphazoline, oxymetazoline, tetrahydrozoline, and xylometazoline), and cycloalkylamines (e.g., propylhexedrine).

A non-limitative example of a mast cell stabilizer is nedocromil sodium.

Non-limitative examples of anti-tussive agents include codeine, dextromethorphan, benzonatate, chlophedianol, and noscapine.

A non-limitative example of an expectorant is guaifenesin.

Non-limitative examples of decongestants are pseudoephedrine,
5 phenylpropanolamine and phenylephrine.

Non-limitative examples of NK₁, NK₂ and NK₃ tachykinin receptor antagonists include CP-99,994 and SR 48968.

Non-limitative examples of GABA_B agonists include baclofen and
3-aminopropyl-phosphinic acid.

10 For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70
15 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax such as a mixture
20 of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Liquid form preparations include solutions, suspensions and
25 emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.

Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions
30 and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or
parenteral administration. Such liquid forms include solutions,
35 suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.

For treating cough, the amount of nociceptin receptor ORL-1 agonist in a unit dose is preferably from about 0.1 mg to 1000 mg, more preferably, from about 1 mg to 300 mg. A typical recommended dosage regimen is oral administration of from 1 mg to 2000 mg/day, preferably 1 to 1000 mg/day, in two to four divided doses. The compounds are non-toxic when administered within this dosage range.

When the nociceptin receptor ORL-1 agonist and one or more additional agents are administered together, they are preferably administered in a combined dosage form (e.g., a single tablet), although they can be administered separately. The additional agents are administered in amounts effective to provide relief from cough, allergy or

asthma symptoms, preferably from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 300 mg per unit dose. A typical recommended dosage regimen of the additional agent is from 1 mg to 2000 mg/day, preferably 1 to 1000 mg/day, in two to four divided doses.

- 5 The following are examples of pharmaceutical dosage forms which contain a compound of the invention. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the examples provided.

Pharmaceutical Dosage Form Examples

EXAMPLE A-Tablets

No.	Ingredients	mg/tablet	mg/tablet
1.	Active compound	100	500
2.	Lactose USP	122	113
3.	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4.	Corn Starch, Food Grade	45	40
5.	Magnesium Stearate	<u>3</u>	<u>7</u>
Total		300	700

10

Method of Manufacture

Mix Item Nos. 1 and 2 in a suitable mixer for 10–15 minutes.

Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10–15 minutes. Add Item No. 5 and mix for 1–3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine.

15

EXAMPLE B-Capsules

No.	Ingredient	mg/capsule	mg/capsule
1.	Active compound	100	500
2.	Lactose USP	106	123
3.	Corn Starch, Food Grade	40	70
4.	Magnesium Stearate NF	<u>7</u>	<u>7</u>
Total		253	700


Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

5 While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. The use of an ORL-1 receptor agonist, alone or in combination with one or more agents for treating cough, allergy or asthma symptoms, to treat cough.
2. The use of claim 1 wherein the ORL-1 agonist is selected from:
- a) a compound represented by the formula




or a pharmaceutically acceptable salt or solvate thereof, wherein:

the dotted line represents an optional double bond;

X¹ is R⁵-(C₁-C₁₂)alkyl, R⁶-(C₃-C₁₂)cycloalkyl, R⁷-aryl, R⁸-heteroaryl or R¹⁰-(C₃-C₇)heterocycloalkyl;


- 15 X² is -CHO, -CN, -NHC(=NR²⁶)NHR²⁶, -CH(=NOR²⁶), -NHR²⁶, R⁷-aryl, R⁷-aryl(C₁-C₆)alkyl, R⁷-aryl(C₁-C₆)alkenyl, R⁷-aryl(C₁-C₆)alkynyl, -(CH₂)_vOR¹³, -(CH₂)_vCOOR²⁷, -(CH₂)_vCONR¹⁴R¹⁵, -(CH₂)_vNR²¹R²² or -(CH₂)_vNHC(O)R²¹, wherein v is zero, 1, 2 or 3 and wherein q is 1 to 3 and a is 1 or 2;

- 20 or X¹ is



and X² is hydrogen;

or X¹ and X² together form a spiro group of the formula



m is 1 or 2;

n is 1, 2 or 3, provided that when n is 1, one of R¹⁶ and R¹⁷ is -C(O)R²⁸;

5 p is 0 or 1;

Q is -CH₂-, -O-, -S-, -SO-, -SO₂- or -NR¹⁷-;

R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen and (C₁-C₆)alkyl, or (R¹ and R⁴) or (R² and R³) or (R¹ and R³) or (R² and R⁴) together can form an alkylene bridge of 1 to 3 carbon atoms;

R⁵ is 1 to 3 substituents independently selected from the group consisting of H, R⁷-aryl, R⁶-(C₃-C₁₂)cycloalkyl, R⁸-heteroaryl, R¹⁰-(C₃-C₇)heterocycloalkyl, -NR¹⁹R²⁰, -OR¹³ and -S(O)₀₋₂R¹³;

15 R⁶ is 1 to 3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, R⁷-aryl, -NR¹⁹R²⁰, -OR¹³ and -SR¹³;

R⁷ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, R²⁵-aryl, (C₃-C₁₂)cycloalkyl, -CN, -CF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -OCF₃, -NR¹⁹R²⁰, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -NHCO₂R¹⁹, -SO₂N(R²⁶)₂, -SO₂R¹⁹, -SOR¹⁹, -SR¹⁹, -NO₂, -CONR¹⁹R²⁰, -NR²⁰COR¹⁹, -COR¹⁹, -COCF₃, -OCOR¹⁹, -OCO₂R¹⁹, -COOR¹⁹, -(C₁-C₆)alkyl-NHCOOC(CH₃)₃, -(C₁-C₆)alkyl-NHCOCF₃, -(C₁-C₆)alkyl-NHCO₂-(C₁-C₆)alkyl, -(C₁-C₆)alkyl-NHCONH-(C₁-C₆)alkyl or -(CH₂)_f-N₂, wherein f is 0 to 6; or R⁷ substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;


25 R⁸ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, R²⁵-aryl, (C₃-C₁₂)cycloalkyl, -CN, -CF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -OCF₃, -NR¹⁹R²⁰, -(C₁-C₆)alkyl-

NR¹⁹R²⁰, -NHSO₂R¹⁹, -SO₂N(R²⁶)₂, -NO₂, -CONR¹⁹R²⁰, -NR²⁰COR¹⁹, -COR¹⁹, -OCOR¹⁹, -OCO₂R¹⁹ and -COOR¹⁹;

R⁹ is hydrogen, (C₁-C₆)alkyl, halo, -OR¹⁹, -NR¹⁹R²⁰, -NHCN, -SR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

5 R¹⁰ is H, (C₁-C₆)alkyl, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

R¹¹ is independently selected from the group consisting of H, R⁵-(C₁-C₆)alkyl, R⁶-(C₃-C₁₂)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl,


-(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰ and $-(CH_2)_q-N$  _a,

10 wherein q and a are as defined above;

R¹² is H, (C₁-C₆)alkyl, halo, -NO₂, -CF₃, -OCF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

R¹³ is H, (C₁-C₆)alkyl, R⁷-aryl, -(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰ or -(C₁-C₆)alkyl-SR¹⁹;

15 R¹⁴ and R¹⁵ are independently selected from the group consisting

of H, R⁵-(C₁-C₆)alkyl, R⁷-aryl and $-(CH_2)_q-C(=O)-N$  _a, wherein q and a are as defined above;

R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, R⁵-(C₁-C₆)alkyl, R⁷-aryl, (C₃-C₁₂)cycloalkyl, R⁸-heteroaryl, R⁸-heteroaryl(C₁-C₆)alkyl, -C(O)R²⁸, -(C₁-C₆)alkyl(C₃-C₇)-heterocycloalkyl, -(C₁-C₆)alkyl-OR¹⁹ and -(C₁-C₆)alkyl-SR¹⁹;

20 R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, aryl and aryl(C₁-C₆)alkyl;


25 R²¹ and R²² are independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, (C₃-C₁₂)cycloalkyl(C₁-C₆)alkyl, (C₃-C₇)heterocycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)-heterocycloalkyl, R⁷-aryl, R⁷-aryl(C₁-C₆)alkyl, R⁸-heteroaryl(C₁-C₁₂)alkyl, -(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -(C₁-C₆)alkyl-SR¹⁹, -(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl and -(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl;

30 C₆)alkyl;

R¹⁸ is hydrogen or (C₁-C₆)alkyl;

Z¹ is R⁵-(C₁-C₁₂)alkyl, R⁷-aryl, R⁸-heteroaryl, R⁶-(C₃-C₁₂)cycloalkyl, R¹⁰-(C₃-C₇)heterocycloalkyl, -CO₂(C₁-C₆)alkyl, CN or -

$C(O)NR^{19}R^{20}$; Z^2 is hydrogen or Z^1 ; Z^3 is hydrogen or (C_1-C_6) alkyl; or Z^1 , Z^2 and Z^3 , together with the carbon to which they are attached, form the group



or $(CHR^{23})_s$, wherein r is 0 to 3; w and u are each 0-3, provided that the sum of w and u is 1-3; c and d are independently 1 or 2; s is 1 to 5; and ring A is a fused R^7 -phenyl or R^8 -heteroaryl ring;

R^{23} is 1 to 3 substituents independently selected from the group consisting of H, (C_1-C_6) alkyl, $-OR^{19}$, $-(C_1-C_6)alkyl-OR^{19}$, $-NR^{19}R^{20}$ and $-(C_1-C_6)alkyl-NR^{19}R^{20}$;

R^{24} is 1 to 3 substituents independently selected from the group consisting of R^{23} , $-CF_3$, $-OCF_3$, NO_2 or halo, or R^{24} substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

R^{25} is 1-3 substituents independently selected from the group consisting of H, (C_1-C_6) alkyl, $(C_1-C_6)alkoxy$ and halo;


R^{26} is independently selected from the group consisting of H, $(C_1-C_6)alkyl$ and $R^{25}-C_6H_4-CH_2-$;

R^{27} is H, $(C_1-C_6)alkyl$, R^7 -aryl $(C_1-C_6)alkyl$, or $(C_3-C_{12})cycloalkyl$;

and

R^{28} is $(C_1-C_6)alkyl$, $-(C_1-C_6)alkyl(C_3-C_{12})cycloalkyl$, R^7 -aryl, R^7 -aryl $-(C_1-C_6)alkyl$, R^8 -heteroaryl, $-(C_1-C_6)alkyl-NR^{19}R^{20}$, $-(C_1-C_6)alkyl-OR^{19}$ or $-(C_1-C_6)alkyl-SR^{19}$;

b) a compound represented by the formula II



25

wherein

R^{1a} and R^{2a} are, independently from each other, hydrogen, lower alkyl, lower alkoxy or halogen;

R^{3a} is phenyl, optionally substituted by lower alkyl, CF_3 , lower alkoxy or halogen; and

- 5 R^{4a} is hydrogen, lower alkyl, lower alkenyl, $-C(O)$ -lower alkyl, $-C(O)$ -phenyl, lower alkyl- $C(O)$ -phenyl, lower alkyl- $-C(O)$ -lower alkyl, lower alkantriyl-di- $C(O)O$ -lower alkyl, hydroxy-lower alkyl, lower alkyl- O -lower alkyl, lower alkyl- $CH(OH)CF_3$, phenyl or benzyl;


- R^{5a} and R^{6a} are, independently from each other, hydrogen, phenyl,
10 lower alkyl or di-lower alkyl or may form together a phenyl ring, and

R^{5a} and one of R^{1a} or R^{2a} may form together a saturated or unsaturated 6 membered ring,

A^a is a 4-7 membered saturated ring which may contain a heteroatom such as O or S,

- 15 or a pharmaceutically acceptable acid addition salt thereof;

c) a compound represented by the structural formula III



III

wherein

- 20 R^{1b} is hydrogen, lower alkyl, halogen, lower alkoxy, CF_3 , lower alkyl-phenyl or (C_{5-7}) -cycloalkyl;


R^{2b} is hydrogen, lower alkyl, phenyl or lower alkyl-phenyl;

- R^{3b} is hydrogen, lower alkyl, benzyl, lower alkyl-phenyl, lower alkyl-diphenyl, triazinyl, cyanomethyl, lower alkyl-piperidinyl, lower alkyl-naphthyl, (C_{5-7}) -cycloalkyl, lower alkyl- (C_{5-7}) -cycloalkyl, lower alkyl-pyridyl,
25 lower alkyl-morpholinyl, lower alkyl dioxolanyl, lower alkyl, oxazolyl, or lower alkyl-2-oxo-oxazolidinyl and wherein the ring systems may be substituted by additional lower alkyl, lower alkoxy, CF_3 or phenyl, or $-(CH_2)_nC(O)O$ -lower alkyl, $-(CH_2)_nC(O)NH_2$, $-(CH_2)_nC(O)N$ (lower alkyl) $_2$, $-(CH_2)_nOH$ or $-(CH_2)_nC(O)NHCH_2C_6H_5$;

- 30 R^{4b} is hydrogen, lower alkyl or nitrilo;

A^b is a ring system, consisting of

(a) (C₅₋₁₅)-cycloalkyl, which may be in addition to R^{4b} optionally substituted by lower alkyl, CF₃, phenyl, (C₅₋₇)-cycloalkyl, spiro-undecan-alkyl or by 2-norbornyl, or is one of the following groups



- 5 dodecahydro-acenaphthylen-1-yl (e), bicyclo[6.2.0]dec-9-yl (f) and bicyclononan-9-yl (g); and wherein


R^{5b} and R^{6b} are hydrogen, lower alkyl, or taken together and with the carbon atoms to which they are attached form a phenyl ring;

R^{7b} is hydrogen or lower alkyl;

- 10 the dotted line represents an optional double bond and
n is 1 to 4;

or a pharmaceutically acceptable acid addition salt thereof;

d) a compound represented by the structural formula IV:



- 15 or a pharmaceutically acceptable salt thereof, wherein

R^{1c} and R^{2c} are independently C₁-C₄ alkyl; or

- R^{1c} and R^{2c}, taken together with the carbon to which they are attached, form a mono-, bi-, tri- or spiro-cyclic group having 6 to 13 carbon atoms, wherein the cyclic group is optionally substituted by 1 to 5 substituents independently selected from C₁-C₄ alkyl, C₂-C₄ alkylene, C₁-C₄ alkoxy, hydroxy, oxo, =CH₂ and =CH-C₁-C₄ alkyl;

- R^{3c} is C₁-C₇ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, phenyl- C₁-C₅ alkyl, phenyl optionally substituted by 1 to 3 substituents independently selected from fluorine, C₁-C₃ alkyl and C₁-C₃ alkoxy, or a heteroaryl group selected from furyl, theinyl, pyrrolyl and pyridyl, wherein said heteroaryl group is optionally substituted by 1 to 3 substituents independently selected from halo, C₁-C₃ alkyl and C₁-C₃ alkoxy, with the proviso that

-82-

when both R^{1c} and R^{2c} are C_1 - C_4 alkyl, then R^{3c} is other than C_1 - C_7 alkyl, C_2 - C_5 alkenyl and C_2 - C_5 alkynyl;

R^{4c} is selected from

1) hydrogen;


5 2) optionally substituted mono- or di-substituted C_1 - C_8 alkyl, C_3 - C_7 cycloalkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, C_1C_6 alkyl- Z^c , C_1C_6 alkyl- Z^c - (C_1C_6) alkyl, C_3 - C_7 cycloalkyl- Z^c - (C_1C_6) alkyl, C_2 - C_6 alkenyl- Z^c - (C_1C_6) alkyl or C_2 - C_6 alkynyl- Z^c - (C_1C_6) alkyl, wherein Z^c is selected from O, S, SO, SO_2 , CO, CO_2 , OCO, NR^c , $CONR^c$ and NR^cCO , wherein R^c is hydrogen or C_1 - C_6 alkyl, and the substituents to be attached to the alkyl, alkenyl, alkynyl or cycloalkyl moiety are independently selected from halo, hydroxy, carboxy, amino, mono- or di- $(C_1$ - C_4 alkyl)amino, hydrazino, azido, ureido, amidino and guanidino; or

3) optionally mono- or di-substituted aryl, heterocyclic, 15 aryl- $(C_1$ - $C_5)$ alkyl, heterocyclic- $(C_1$ - $C_5)$ alkyl, heterocyclic-heterocyclic- $(C_1$ - $C_5)$ alkyl, aryl-heterocyclic- $(C_1$ - $C_5)$ alkyl, heterocyclic- Z^c - $(C_1$ - $C_5)$ alkyl, aryl- Z^c - $(C_1$ - $C_5)$ alkyl, aryl- $(C_1$ - $C_5)$ alkyl- Z^c - $(C_1$ - $C_5)$ alkyl, or heterocyclic- $(C_1$ - $C_5)$ alkyl- Z^c - $(C_1$ - $C_5)$ alkyl, wherein Z^c is selected from O, S, SO, SO_2 , CO, CO_2 , OCO, NR^c , $CONR^c$ and NR^cCO , wherein R^c is hydrogen or C_1 - C_6 alkyl, and the 20 substituents to be attached to the aryl or heterocyclic moiety are independently selected from halo, hydroxy, carboxy, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 alkyl-CO-, amino- $(C_1$ - $C_4)$ alkyl-CO-, phenyl, benzyl, amino, mono- or di- $(C_1$ - C_4 alkyl)amino, hydrazino, azido, ureido, amidino and guanidino;

25 R^{5c} is independently selected from halo, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 alkylsulfonyl, CF_3 , carboxy, hydroxy, amino, alkylamino, acylamino, arylcarbonyl, alkylcarbonyl and hydroxyalkyl; and

n is 0, 1, 2, 3 or 4;


e) a compound represented by the structural formula V



30

or a salt or ester thereof, wherein

Ar^{1d} is an optionally substituted aromatic carbon ring or heterocycle, wherein the optional substituents are independently selected from halo, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy and carboxyl;


5  is an optionally substituted mono- or di-cyclic C₃₋₁₄ aliphatic nitrogenous heterocycle;

Cy^d is an optionally substituted mono-, di- or tri-cyclic C₃₋₂₀ aliphatic carbon ring;

10 R^{1d} is hydrogen, lower alkenyl, lower alkynyl, lower cycloalkyl, amino, lower alkylamino, di(lower alkyl)amino, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di(lower alkyl)carbamoyl or optionally substituted lower alkyl; and

R^{2d} is hydrogen or lower alkyl; and

f) a compound represented by the structural formula VI



or a pharmaceutically acceptable salt thereof, wherein

A^e is an aryl or heterocyclyl ring;

B^e is phenyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, oxazolyl or cyclohexenyl;

20 R^{1e} and R^{2e} are independently hydrogen, alkyl, hydroxyalkyl, amino, alkylamino or di-alkylamino;

R^{3e} and R^{4e} are independently hydrogen, halo or alkyl;

X^e is hydrogen, halo, alkyl, alkoxyalkyl, alkenyl, amino, CN, or -(CH₂)_{me}-E^e-(CH₂)_{ne}-G^e;

25 E^e is a bond, -CH=CR^{6e}, O, S, NR^{7e}, CO, SO₂ or NHCO;

G^e is aryl, heterocyclyl, cycloalkyl or fused aryl, all optionally substituted by 1-5 R^{5e} groups;

30 R^{5e} is independently selected from halo, OH, alkyl, alkyl optionally substituted by alkoxy, alkoxyalkoxy, halo, OH or alkanoyloxy, alkoxy, alkoxyalkoxy, amino, alkylamino, di-alkylamino, NO₂, CN, alkanoyl, alkanoyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl and phenyl;

R^{6e} is hydrogen or aryl;

R^{7e} is hydrogen, alkyl or alkoxycarbonyl;

-84-

m^e is 0-8; and


n^e is 1-4.


3. The use of claim 2 wherein the compound is represented by
5 structural formula I.

4. The use of claim 3 wherein, in the compound of formula I, Z^1 and Z^2 are each R^7 -aryl.


10 5. The use of claim 4, wherein R^7 is selected from the group consisting of (C_1-C_6) alkyl and halo.

6. The use of claim 3 wherein, in the compound of formula I, X^1 is R^7 -aryl and X^2 is OH; or X^2 is hydrogen and X^1 is


15  ; or X^1 and X^2 together form the spirocyclic group



7. The use of claim 6 wherein X^1 is













20 , R^{12} is hydrogen and R^{11} is (C_1-C_6) alkyl, $-(C_1-C_6)$ alkyl (C_3-C_{12}) cycloalkyl, $-(C_1-C_6)$ alkyl-OR¹⁹ or $-(C_1-C_6)$ alkyl-NR¹⁹R²⁰.

8. The use of claim 6 wherein X^1 and X^2 together form




, m is 1, R^{17} is phenyl and R^{11} is $-(C_1-C_6)$ alkyl-OR¹⁹ or $-(C_1-C_6)$ alkyl-NR¹⁹R²⁰.

9. The use of claim 2 wherein the ORL-1 agonist is selected from



-86-



10. The use of claim 1 wherein the agents for treating cough, allergy or asthma symptoms are selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists.
11. The use of an ORL-1 receptor agonist, alone or in combination with one or more agents for treating cough, allergy or asthma symptoms, for the manufacture of a medicament for treating cough.
12. A pharmaceutical composition comprising: a therapeutically effective amount of a nociceptin receptor ORL-1 agonist; a therapeutically effective amount of one or more agents selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene

-87-

- inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, decongestants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists; and a pharmaceutically
- 5 acceptable carrier.

1/4




FIG. 1

*P<0.05 COMPARED TO CONTROLS USING AN ANOVA IN CONJUNCTION WITH A DUNNETT'S T-TEST




FIG. 2A




FIG. 2B

4/4




FIG. 2C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/01853

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/445 A61K31/46 A61K45/06 A61P11/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 195 19 245 A (BOEHRINGER INGELHEIM KG) 17 October 1996 (1996-10-17) page 4, line 66; claims 1,10	1-3,11
Y	claims 10,11	10,12
X	GB 1 052 302 A (NOT APPLICABLE) 21 December 1966 (1966-12-21) page 1, line 8 - line 10 page 2, line 15 claims 1,56	1-3,11
Y	claims 56,61,62	10,12
Y	WO 98 52545 A (BARRETT DAVID MICHAEL ; JONES HUW LYN (GB); JONES IDWAL (GB); BOOTS) 26 November 1998 (1998-11-26) page 13; claim 1	10,12
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 May 2000

Date of mailing of the international search report

06/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Brunnauer, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/01853

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 00 06545 A (SCHERING CORPORATION US) 10 February 2000 (2000-02-10) claims 1-15</p> <p>-----</p>	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/01853

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19519245 A	17-10-1996	AU 706209 B	10-06-1999
		AU 5687496 A	30-10-1996
		BG 62138 B	31-03-1999
		BG 101947 A	29-05-1998
		BR 9604821 A	09-06-1998
		CA 2218096 A	17-10-1996
		CZ 9703257 A	17-06-1998
		WO 9632386 A	17-10-1996
		EP 0824530 A	25-02-1998
		HR 960168 A	31-08-1997
		HU 9802270 A	28-09-1999
		JP 11503441 T	26-03-1999
		NO 974734 A	13-10-1997
		PL 322768 A	16-02-1998
		SK 138797 A	04-03-1998
		US 5710155 A	20-01-1998
		US 5861509 A	19-01-1999
		ZA 9602916 A	14-10-1996
GB 1052302 A		CH 436290 A	
		CH 436293 A	
		FR 3846 M	
		FR 1555457 A	31-01-1969
		US 3311624 A	28-03-1967
WO 9852545 A	26-11-1998	AU 7916798 A	11-12-1998
WO 0006545 A	10-02-2000	NONE	